Department of State Division of Publications

312 Rosa L. Parks Avenue, 8th Floor Snodgrass/TN Tower

Nashville, TN 37243 Phone: 615-741-2650

Email: publications.information@tn.gov

For Department of State Use Only

Sequence Number: 03-20-17

Rule ID(s): <u>6470</u>

Rulemaking Hearing Rule(s) Filing Form

Rulemaking Hearing Rules are rules filed after and as a result of a rulemaking hearing (Tenn. Code Ann. § 4-5-205).

Pursuant to Tenn. Code Ann. § 4-5-229, any new fee or fee increase promulgated by state agency rule shall take effect on July 1, following the expiration of the ninety (90) day period as provided in § 4-5-207. This section shall not apply to rules that implement new fees or fee increases that are promulgated as emergency rules pursuant to § 4-5-208(a) and to subsequent rules that make permanent such emergency rules, as amended during the rulemaking process. In addition, this section shall not apply to state agencies that did not, during the preceding two (2) fiscal years, collect fees in an amount sufficient to pay the cost of operating the board, commission or entity in accordance with § 4-29-121(b).

Agency/Board/Commission:	Tennessee Department of Mental Health and Substance Abuse Services
Division:	Division of Substance Abuse Services
Contact Person:	Kurt Hippel, Office of Legislation, Rules & Privacy
Address:	500 Deaderick Street, 5th Floor, Andrew Jackson Building
Zip:	37243
Phone:	615-532-6520
Email:	Kurt.Hippel@tn.gov

Revision Type (check all that apply):

Amendment

X New

X Repeal

Rule(s) (**ALL** chapters and rules contained in filing must be listed here. If needed, copy and paste additional tables to accommodate multiple chapters. Please make sure that **ALL** new rule and repealed rule numbers are listed in the chart below. Please enter only **ONE** Rule Number/Rule Title per row)

Chapter Number	Chapter Title
0940-06-01	Controlled Substances
Rule Number	Rule Title
0940-06-0101	Controlled Substances in Schedule I
0940-06-0102	Controlled Substances in Schedule II
0940-06-0103	Controlled Substances in Schedule III
0940-06-0104	Controlled Substances in Schedule IV
0940-06-0105	Controlled Substances in Schedule V
0940-06-0106	Controlled Substances in Schedule VI
0940-06-0107	Controlled Substances in Schedule VII
0940-06-0108	Non-Narcotic Substances Excluded from Controlled Substances
0940-06-0109	Chemical preparations excluded from Controlled Substances
0940-06-0110	Veterinary anabolic steroid implant products excluded from Controlled Substances
0940-06-0111	Prescription products excluded from Controlled Substances
0940-06-0112	Anabolic steroid products excluded from Controlled Substances
0940-06-0113	Certain cannabis plant material, and products made therefrom, excluded from Controlled Substances

(Place substance of rules and other info here. Please be sure to include a detailed explanation of the changes being made to the listed rule(s). Statutory authority must be given for each rule change. For information on formatting rules go to http://sos.tn.gov/sites/default/files/forms/Rulemaking Guidelines August2014.pdf)

Chapter 0940-06-01 Controlled Substances

Chapter 0940-06-01 Controlled Substances is being repealed and rewritten including its table of contents.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

Chapter 0940-06-01 Controlled Substances

New Rule

0940-06-01-.01 Controlled Substances in Schedule I.

- (1) Schedule I consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation. For the purposes of subparagraph (II) 3-Methylfentanyl, only, the term isomer includes the optical and geometric isomers.

(a)	Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidnyl]-N-phenyl-acetamide)	
(b)	Acetylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)	9821
(c)	Acetylmethadol	9601
(d)	Allylprodine	9602
(e)	Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol; levomethadyl acetate; or LAAM)	9603
(f)	Alphameprodine	9604
(g)	Alphamethadol	.9605
(h)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionar 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine)	
(i)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)	9832
(j)	Benzethidine	9606
(k)	Betacetylmethadol	9607
(i)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-	

	phenylpropanamide)	3830
(m)	Beta-hydroxythiofentanyl9 Other name: N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropion N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide	9836 ıamide,
(n)	Beta-hydroxy-3-methylfentanyl 9 Other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropan	
(0)	Betameprodine9	9608
(p)	Betamethadol9	9609
(q)	Betaprodine9	9611
(r)	Butyryl Fentanyl9 Other name: N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide	
(s)	Clonitazene9	612
(t)	Dextromoramide9	9613
(u)	Diampromide9	615
(v)	Diethylthiambutene 9	616
(w)	Difenoxin9	168
(x)	Dimenoxadol9	617
(y)	Dimepheptanol9	618
(z)	Dimethylthiambutene9	619
(aa)	Dioxaphetyl butyrate9	621
(bb)	Dipipanone9	622
(cc)	Ethylmethylthiambutene9	623
(dd)	Etonitazene9	624
(ee)	Etoxeridine9	625
(ff)	Furethidine9	626
(gg)	Furanyl Fentanyl9	834
(hh)	Hydroxypethidine9	627
(ii)	Ketobemidone9	628
(jj)	Levomoramide9	629
(kk)	Levophenacylmorphan9	631
(11)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide)9	813

(mm)	phenylpropanamide)phenylpropanamide)	. 9833
(nn)	Morpheridine	9632
(00)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	9661
(pp)	Noracymethadol	9633
(qq)	Norlevorphanol	9634
(rr)	Normethadone	9635
(ss)	Norpipanone	9636
(tt)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide)	9812
(uu)	PEPAP (1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine)	9663
(vv)	Phenadoxone	9637
(ww)	Phenampromide	9638
(xx)	Phenomorphan	.9647
(yy)	Phenoperidine	9641
(zz)	Piritramide	9642
(aaa)	Proheptazine	9643
(bbb)	Properidine	9644
(ccc)	Propiram	9649
(ddd)	Racemoramide	9645
(eee)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide)	9835
(fff)	Tilidine	9750
(ggg)	Trimeperidine	9646
(hhh)	U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide	9547
followin	derivatives. Unless specifically excepted or unless listed in another schedule, any g opium derivatives, its salts, isomers, and salts of isomers, whenever the existentials, isomers, and salts of isomers is possible within the specific chemical designation.	ce of
(a)	Acetorphine	9319
(b)	Acetyldihydrocodeine	9051
(c)	Benzylmorphine	9052
(d)	Codeine methylbromide	9070
(e)	Codeine-N-Oxide	9053

(3)

	(f)	Cyprenorphine	. 9054
	(g)	Desomorphine	9055
	(h)	Dihydromorphine	.9145
	(i)	Drotebanol	9335
	(j)	Etorphine (except hydrochloride salt)	. 9056
	(k)	Heroin	9200
	(1)	Hydromorphinol	9301
	(m)	Methyldesorphine	9302
	(n)	Methyldihydromorphine	.9304
	(0)	Morphine methylbromide	9305
	(p)	Morphine methylsulfonate	9306
	(q)	Morphine-N-Oxide	9307
	(r)	Myrophine	.9308
	(s)	Nicocodeine	9309
	(t)	Nicomorphine	9312
	(u)	Normorphine	9313
	(v)	Pholcodine	9314
×	(w)	Thebacon	9315
(4)	materia hallucir whenev specifie	nogenic substances. Unless specifically excepted or unless listed in another schedal, compound mixture, or preparation, which contains any quantity of the following nogenic substances, or which contains any of its salts, isomers, and salts of isomer wer the existence of such salts, isomers, and salts of isomers, is possible within the ed chemical designation (for purposes of this paragraph only, the term "isomer" inclinal, position and geometric isomers):	rs
	(a)	Alpha-ethyltryptamine Other names: etryptamine; Monase; [alpha]-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; [alpha]-ET; and AET; ET; Trip	.7249
	(b)	Alpha-methyltryptamine Other name: AMT	7432
	(c)	4-Bromo-2,5-dimethoxyamphetamineOther names: 4-Bromo-2,5-dimethoxy-[alpha]-methylphenethylamine; 4-bromo-2,	7391 5-DMA
	(d)	4-Bromo-2,5-dimethoxyphenethylamineOther names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethy 2C-B; Nexus	
	(e)	2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36	7536

(f)	Bufotenine
(g)	2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(h)	Diethyltryptamine
(i)	2,5-Dimethoxyamphetamine
(j)	2, 5-Dimethoxy-4-ethylamphetamine
(k)	2, 5 Dimethoxy-4-(n)-propylthiophenethylamine
(1)	Dimethyltryptamine
(m)	Ethylamine analog of phencyclidine
(n)	Ibogaine
(o)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(p)	Lysergic acid diethylamide
(q)	Mescaline
(r)	4-Methoxyamphetamine
(s)	5-Methoxy-3,4-methylenedioxyamphetamine
(t)	5-Methoxy-N,N-diisopropyltryptamine
(u)	5-methoxy-N,N-dimethyltryptamine
(v)	4-Methyl-2, 5-dimethoxyamphetamine
(w)	3,4-Methylenedioxyamphetamine
(x)	3,4-Methylenedioxymethamphetamine

(y)	3,4-Methylenedioxy-N-ethylamphetamine
(z)	3,4-Methylenedioxy-N-methylcathinone
(aa)	N-Ethyl-3-piperidyl benzilate
(bb)	N-Hydroxy-3,4-methylenedioxyamphetamine
(cc)	N-methyl-3-piperidyl benzilate
(dd)	Parahexyl
(ee)	Peyote
(ff)	Psilocybin (constituent of magic mushrooms)
(gg)	Psilocyn (constituent of magic mushrooms)
(hh)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine)
(ii)	1-[1-(2-Thienyl)cyclohexyl]pyrrolidine
(jj)	4- Methylmethcathinone
(kk)	3,4-Methylenedioxypyrovalerone
(II)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)
(mm)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)
(nn)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)
(00)	2-(4-lodo-2,5-dimethoxyphenyl)ethanamine (2C-I)
(pp)	2-[4-Ethylthio-2,5-dimethoxyphenyl]ethanamine (2C-T-2)
(pp)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)
(rr)	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)
(ss)	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)
(tt)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)
(uu)	Thiophene analog of phencyclidine

		Other names: 1-[1-(2-thienyl)cyclohexyl]piperidine; 2-thienylanalog of phencyclidine; TPCP; TCP
	(vv)	3,4,5-Trimethoxyamphetamine
	(ww)	(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
	(xx)	1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 7011 Other names: 5-fluoro-UR-144; 5-F-UR-144; XLR11; 1-(5-fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole
(5)	compo having isome	ssants. Unless specifically excepted or unless listed in another schedule, any material, bund, mixture, or preparation which contains any quantity of the following substances a depressant effect on the central nervous system, including its salts, isomers, and salts of rs whenever the existence of such salts, isomers, and salts of isomers is possible within the field chemical designation:
	(a)	Etizolam Other names; Etilaam, Etizola, Sedekopan, Pasaden, Depas
	(b)	Gamma-hydroxybutyric acid
	(c)	Mecloqualone
	(d)	Methaqualone2565
compound, mixture, or preparation which contains any quantity of the following		ants. Unless specifically excepted or unless listed in another schedule, any material, bund, mixture, or preparation which contains any quantity of the following substances a stimulant effect on the central nervous system, including its salts, isomers, and salts of rs:
	(a)	Alpha-pyrrolidinobutiophenone
	(b)	Alpha-pyrrolidinopentiophenone
	(c)	Aminorex
	(d)	Butylone
	(e)	Cathinone
	(f)	3-Fluoro-N-methylcathinone
	(g)	4-Fluoro-N-methylcathinone
	(h)	Fenethylline1503

	(i)	Methcathinone Other names: 2-(methylamino)-propiophenone; alpha-(methylamino) propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; A AL-463; and UR1432;	ne;
	(j)	(+/-) <i>cis</i> -4-Methylaminorex (cis isomer)	1590
	(k)	4-Methyl-N-ethylcathinone Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one	1249
	(1)	4-Methyl-alpha-pyrrolidinopropiophenone	7498 1-
	(m)	Naphyrone Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan	1258 -1-one
	(n)	N-BenzylpiperazineOther names: BZP; 1-benzylpiperazine	7493
	(0)	N-Ethylamphetamine	1475
	(p)	N,N-DimethylamphetamineOther names: N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine	1480
	(q)	Pentedrone, Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentone	
	(r)	Pentylone Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one	7542
	materia substar	pimimetic agents. Unless specifically exempted or unless listed in another schedule al, compound, mixture, or preparation which contains any quantity of the following nces, or which contains their salts, isomers, and salts of isomers whenever the exis salts; isomers, and salts of isomers is possible within the specific chemical design	stence
	(a)	5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497)	7297
	(b)	5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexar CP-47,497 C8-homolog)	nol or 7298
	(c)	1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)	7118
	(d)	1-Butyl-3-(1-naphthoyl)indole (JWH-073)	7173
	(e)	1-Hexyl-3-(1-naphthoyl)indole (JWH-019)	7019
	(f)	1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)	7200
	(g)	1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)	6250
	(h)	1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)	7081
	(i)	1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)	7122
	(j)	1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)	7398
ıne	2016)	9 RDA 1693	

(7)

(k)	(1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ-2201)	7024
(I)	1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)	.7201
(m)	1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)	7694
(n)	1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4)	.7104
(0)	1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8)	7008
(p)	1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)	7203
(q)	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide Other names: APINACA; AKB48	7048
(r)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide Other names: AB-FUBINACA	. 7012
(s)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3-carboxamide Other names: AB-CHMINACA	7031
(t)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide Other names: ADB-PINACA	7035
(u)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide Other names: AB-PINACA	7023
(v)	Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	7225
(w)	Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate Other names: PB-22; QUPIC	.7222
. §§ 4-4	-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.	

Authority: T.C.A

Codeine

0940-06-01-.02 Controlled Substances in Schedule II.

- (1) Schedule II consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2)Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
 - Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, (a) excluding apomorphine, dextrorphan, thebaine-derived butorphanol, nalmefene, nalbuphine, naloxone, and naltrexone, and their respective salts, but including the following:

1.	Codeine	9050
2.	Dihydroetorphine	9334
2	Ethylmarphina	0100

	٦.	Ltorprime nydrocinonae					
	5.	Granulated opium9640					
	6.	Hydrocodone9193					
	7.	Hydromorphone					
¥1	8.	Metopon					
	9.	Morphine					
	10.	Opium extracts9610					
	11.	Opium fluid 9620					
	12.	Oripavine					
	13.	Oxycodone					
	14.	Oxymorphone9652					
	15.	Powdered opium					
	16.	Raw opium					
	17.	Thebaine					
	18.	Tincture of opium9630					
(b)	identic	Ilt, compound, derivative, or preparation thereof which is chemically equivalent or all with any of the substances referred to in paragraph (2)(a) of this rule, except that substances shall not include the isoquinoline alkaloids of opium.					
(c)	Opium	poppy and poppy straw.					
(d)	Coca leaves (9040) and any salt, compound, derivative or preparation of coca leaves (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.						
(e)	Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy) 9670						
includi exister	ng its isc nce of su	s specifically excepted or unless in another schedule any of the following opiates, omers, esters, ethers, salts and salts of isomers, esters and ethers whenever the och isomers, esters, ethers, and salts is possible within the specific chemical extrorphan and levopropoxyphene excepted:					
(a)	Alfenta	nil9737					
(b)	Alphap	prodine					
(c)	Anilerio	dine9020					
(d)	Bezitra	mide9800					

Etorphine hydrochloride.......9059

(3)

4.

(e)	Carfentanil9	743
(f)	Dextropropoxyphene (bulk, non dosage forms)9	273
(g)	Dihydrocodeine9	120
(h)	Diphenoxylate9	170
(i)	Fentanyl9	9801
(j)	Isomethadone 9	226
(k)	Levo-alphacetylmethadol	1648
(1)	Levomethorphan9	210
(m)	Levorphanol9	220
(n)	Metazocine9	240
(0)	Methadone9	250
(p)	Methadone-Intermediate; 4-cyano-2-dimethylamino-4,4-diphenyl butane 9	1254
(q)	Moramide-Intermediate; 2-methyl-3-morpholino-1,1-diphenylpropane-caboxylic acid	802
(r)	Pethidine (meperidine)9	230
(s)	Pethidine-Intermediate-A; 4-cyano-1-methyl-4-phenylpiperidine9	232
(t)	Pethidine-Intermediate-B; ethyl-4-phenylpiperidine-4-carboxylate9	233
(u)	Pethidine-Intermediate-C; 1-methyl-4-phenylpiperidine-4-carboxylic acid 9	234
(v)	Phenazocine 9	715
(w)	Piminodine9	730
(x)	Racemethorphan9	732
(y)	Racemorphan9	733
(z)	Remifentanil9	739
(aa)	Sufentanil9	740
(bb)	Tapentadol9	780
(cc)	Thiafentanil9	729
compoi	ants. Unless specifically excepted or unless listed in another schedule, any material, und, mixture, or preparation which contains any quantity of the following substances a stimulant effect on the central nervous system:	
(a)	Amphetamine, its salts, optical isomers, and salts of its optical isomers	100
(b)	Methamphetamine, its salts, isomers, and salts of its isomers	105

(4)

	(c)	Phenr	netrazine and its salts	1631		
	(d)	Methy	Iphenidate	1724		
	(e)	Lisdex	camfetamine, its salts, isomers, and salts of its isomers	1205		
(5)	compo having isome	ound, mi g a depre rs when	Unless specifically excepted or unless listed in another schedule any matexture, or preparation which contains any quantity of the following substancessant effect on the central nervous system, including its salts, isomers, a ever the existence of such salts, isomers, and salts of isomers is possible cal designation:	ces nd salts of		
	(a)	Amob	arbital	2125		
	(b)	Glutet	himide	2550		
	(c)	Pento	barbital	2270		
	(d)	Pheno	yclidine	7471		
	(e)	Secob	parbital	2315		
(6)	Halluc	inogenio	substances.	χ.		
	(a)	Other	nenames: (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-h ethyl-9H-dibenzo[b,d]pyran-9-one.			
(7)	mater	Immediate precursors. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances:				
	(a)	Immed	diate precursor to amphetamine and methamphetamine:			
		1.	Phenylacetone	8501		
			Other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl ketone;	benzyl		
	(b)	Immed	diate precursors to phencyclidine (PCP):			
		1.	1-phenylcyclohexylamine	7460		
		2.	1-piperidinocyclohexanecarbonitrile(PCC)	8603		
	(c)	Immed	diate precursor to fentanyl:			
		1.	4-anilino-N-phenethyl-4-piperidine (ANPP)	8333		
Authority: T.C.	A. §§ 4-	4-103, 3	3-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.			
0940-06-010	3 Contro	lled Sub	ostances in Schedule III.			
(1)	usual substa	name, cl ince bea	onsists of the drugs and other substances by whatever official name, com- nemical name, or brand name designated, listed in this rule. Each drug or ars the federal controlled substance code number assigned to it by the Dru administration.			

(2) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances

having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

	(a)	stimula were lis any oth is the s	compounds, mixtures, or preparations in dosage unit form containing a ant substances listed in Schedule II which compounds, mixtures, or prested on August 25, 1971, as excepted compounds under 21 C.F.R. 130 ner drug of the quantitative composition shown in that list for those drug same except that it contains a lesser quantity of controlled not not not the controlled not control	parations 08.32, and us or which
	(b)	Benzpl	hetamine	1228
	(c)	Clorph	entermine	1645
	(d)	Clorter	mine	1647
	(e)	Phend	imetrazine	1615
(3)	compo	ound, mix	Unless specifically excepted or unless listed in another schedule, any mature, or preparation which contains any quantity of the following substants effect in the central nervous system:	
	(a)	Any co	ompound, mixture, or preparation containing:	
		1.	Amobarbital	2126
		2.	Secobarbital	2316
		3.	Pentobarbital Or any salt thereof and one or more other active medicinal ingredient not listed in any schedule.	
	(b)	Any su	ppository dosage form containing:	
		1.	Amobarbital	2126
		2.	Secobarbital	2316
		3.	PentobarbitalOr any salt of these drugs and approved by the Food and Drug Admir marketing only as a suppository.	
	(c)		ubstance which contains any quantity of a derivative of barbituric acid of Examples include the following drugs:	
		1.	Aprobarbital	2100
		2.	Butabarbital (secbutabarbital)	0400
		۷.	Dulabarbilar (Secoulabarbilar)	2100
		3.	Butalbital	
				2100
		3.	Butalbital	2100
		3. 4.	Butalbital Butobarbital (butethal)	2100 2100 2100
		3.4.5.	Butalbital Butobarbital (butethal) Talbutal	2100 2100 2100 2100

		8.	Vinbarbital	2100		
	(d)	Chlorhe	exadol	2510		
	(e)	Embutr	amide	2020		
	(f)	hydroxy applica codified	a hydroxybutyric acid preparations. Any drug product containing gamma ybutyric acid, including its salts, isomers, and salts of isomers, for which artion is approved under § 505 of the federal Food, Drug, and Cosmetic Act, d in 21 U.S.C. §_301, et			
	(g)		ne, its salts, isomers, and salts of isomersname: (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone	7285		
	(h)	Lysergi	ic acid	7300		
	(i)	Lysergi	ic acid amide	7310		
	(j)	Methyp	prylon	2575		
	(k)	Peram	panel, and its salts, isomers, and salts of isomers	2261		
	(l)	Sulfond	diethylmethane	2600		
	(m)	Sulfone	ethylmethane	2605		
	(n)	Sulfonmethane				
	(0)	Tiletamine and zolazepam or any salt of tiletamine or zolazepam				
		1.	Other name for a tiletamine-zolazepam combination product: Telazol®;			
		2.	Other name for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.			
		3.	Other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo[3,4-e],[1,4]-diazepin-7(1H)-one; flupyrazapon			
(4)	Nalorpl	hine		9400		
(5)	Narcoti	c Drugs.	€			
	(a)	compo	specifically excepted or unless listed in another schedule, any material, und, mixture, or preparation containing any of the following narcotic drugs, alculated as the free anhydrous base or alkaloid, in limited quantities as set			
		1,	Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquin alkaloid of opium.	oline		
		2.	Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredie recognized therapeutic amounts	ents in		
		3.	Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more 90 milligrams per dosage unit with one or more active non-narcotic ingred recognized therapeutic amount.	dients in		

		4.	Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit with one or more active non-narcotic ingredients in recognized therapeutic amounts
		5.	Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts
		6.	Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, non-narcotic ingredients in recognized therapeutic amounts
	(b)		naterial, compound, mixture, or preparation containing any of the following narcotic or their salts:
		1.	Buprenorphine9064
(6)	materi	al, comp	ids. Unless specifically excepted or unless listed in another schedule, any bound, mixture, or preparation containing any quantity of the following substances, alts, esters and ethers:
	(a)	Anabo	lic steroids
		1.	3[alpha],17[beta]-dihydroxy-5a-androstane
		2.	17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane
		3.	17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5a-androstane
		4.	17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene
		5.	17[alpha]-methyl-[delta]1-dihydrotestosterone(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one Other Names: 17-[alpha]-methyl-1-testosterone
		6.	17[alpha]-methyl-4-hydroxynandrolone(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one)
		7.	1-Androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene)
		8.	1-Androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene)
		9.	4-Androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene)
		10.	5-Androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene)
		11.	1-Androstenedione (5[alpha]-androst-1-en-3,17-dione)
		12.	4-Androstenedione (androst-4-en-3,17-dione)
		13.	5-Androstenedione (androst-5-en-3,17-dione)
		14.	3[Beta],17[Beta]-dihydroxy-5a-androstane
		15.	13[Beta]-ethyl-17[beta]-hydroxygon-4-en-3-one
		16.	Androstanedione (5[alpha]-androstan-3,17-dione)
		17.	Bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one)

- 18. Boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one)
- 19. Boldione (androsta-1,4-diene-3,17-dione)
- 20. Calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one)
- 21. Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one)
 Other Names: 4-Chlorotestosterone
- 22. Dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one)
- 23. [Delta]1-dihydrotestosterone (a.k.a.'1-testosterone') (17[Beta]-hydroxy-5[alpha]-androst-1-en-3-one)
- 24. Desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[Beta]-ol) Other name: madol
- 25. 4-Dihydrotestosterone (17[beta]-hydroxyandrostan-3-one)
- 26. Drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one)
- 27. Ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene)
- 28. Fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one)
- Formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one)
- 30. Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)
- 31. 4-Hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one)
- 32. 4-Hydroxytestosterone (4,17[beta]-dihydroxyandrost- 4-en-3-one)
- 33. Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one)
- 34. Mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one)
- 35. Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-diene-3-one)
- 36. Methandranone
- 37. Methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene)
- 38. Methandrostenolone
- 39. Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one)
- 40. Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one)
- 41. Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one)
- 42. Methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one)
- 43. Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4, 9,11-trien-3-one)
- 44. Mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one)

- 45. Nandrolone (17[beta]-hydroxyestr-4-en-3-one)
- 46. 19-Nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)
- 47. 19-Nor-4-androstenediol (3[alpha],17[beta]-dihydroxyestr-4-ene)
- 48. 19-Nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene)
- 49. 19-Nor-5-androstenediol (3[alpha],17[beta]-dihydroxyestr-5-ene)
- 50. 19-Nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene)
- 51. 19-Nor-4-androstenedione (estr-4-en-3,17-dione)
- 52. 19-Nor-5-androstenedione (estr-5-en-3,17-dione)
- 53. Norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one)
- 54. Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one)
- 55. Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one)
- 56. Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one)
- 57. Oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one)
- 58. Oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one)
- 59. Oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-[5[alpha]]-androstan-3-one)
- 60. Prostanozol (17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pryazole)
- 61. Stanolone (17[beta]-Hydroxy-5alpha-Androstan-3-One)
- 62. Stanozolol (17[alpha]-methyl-17[beta]-hydroxy-[5[alpha]]-androst-2-eno[3,2-c]-pyrazole)
- 63. Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3-one)
- 64. Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1, 4-dien-17-oic acid lactone)
- 65. Testosterone (17[beta]-hydroxyandrost-4-en-3-one)
- 66. Tetrahydrogestrinone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4, 9,11-trien-3-one)
- 67. Trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one)
- (b) Any salt, ester, or isomer of a drug or substance described or listed in subparagraph (a), if such salt, ester, or isomer promotes muscle growth.
- (c) Anabolic steroids intended for administration to cattle or other non-human species are exempt from this rule unless such steroids are prescribed, dispensed, or distributed for human use.
- (d) Anabolic steroids with a combination of estrogens intended for administration to hormone deficient women are exempt from this rule unless such steroids are prescribed,

dispensed, or distributed to women who are not hormone deficient.

(7) Hallucinogenic Substances

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.04 Controlled Substances in Schedule IV.

- (1) Schedule IV consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
- (3) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substance, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(a)	Alfaxalone	2731
(b)	Alprazolam	2882
(c)	Barbital	2145
(d)	Bromazepam	2748
(e)	Camazepam	2749
(f)	CarisoprodolOther name: Soma®	8192
(g)	Chloral betaine	2460
(h)	Chloral hydrate	2465
(i)	Chlordiazepoxide	2744
(j)	Clobazam	2751
(k)	Clonazepam	2737
(1)	Clorazepate	2768
(m)	Clotiazepam	2752

(n)	Cloxazolam27	53
(o)	Delorazepam27	'54
(p)	Diazepam	65
(p)	Dichloralphenazone	67
(r)	Estazolam	'56
(s)	Eszopiclone	Α
(t)	Ethchlorvynol	34 C
(u)	Ethinamate	45
(v)	Ethyl Loflazepate27	'58
(w)	Fludiazepam27	'59
(x)	Flunitrazepam	'63
(y)	Flurazepam	'67
(z)	Fospropofol21	138
(aa)	Halazepam	'62
(bb)	Haloxazolam	'71
(cc)	Ketazolam27	'72
(dd)	Loprazolam27	'73
(ee)	Lorazepam28	385
(ff)	Lormetazepam27	774
(gg)	Mebutamate	300
(hh)	Medazepam	36
(ii)	Meprobamate	320
(jj)	Methohexital22	264
(kk)	Methylphenobarbital (mephobarbital)22	25C
(II)	Midazolam	384
(mm)	Nimetazepam	337
(nn)	Nitrazepam	334
(00)	Nordiazepam28	38
(pp)	Oxazepam	35
(qq)	Oxazolam	38

	(rr)	Paraldehyde	2585
	(ss)	Petrichloral	2591
	(tt)	Phenobarbital	2285
	(uu)	Pinazepam	2883
	(vv)	Prazepam	2764
	(ww)	Quazepam	. 2881
	(xx)	Suvorexant	2223
	(yy)	Temazepam	2925
	(zz)	Tetrazepam	2886
	(aaa)	TramadolOther names: Ultram® and Ultracet®	9752
	(bbb)	Triazolam	2887
	(ccc)	Zaleplon	2781
	(ddd)	Zolpidem	2783
	(eee)	Zopiclone	2784
(4)	followin	amine. Any material, compound, mixture, or preparation which contains any quaring substances including its salts, isomers (whether optical, positional, or geometrifisomers, whenever the existence of such salts, isomers, and salts of isomers is presented.	c), and
	(a)	Fenfluramine	1670
	(b)	Dexfenfluramine	1670
(5)	followin	erin. Any material, compound, mixture, or preparation which contains any quantity ng substances, including its salts, isomers, and salts of such isomers, whenever the ce of such salts, isomers, and salts of isomers is possible:	
	(a)	Lorcaserin	. 1625
(6)	compou	ants. Unless specifically excepted or unless listed in another schedule, any materiund, mixture, or preparation which contains any quantity of the following substance a stimulant effect on the central nervous system, including its salts, isomers and s:	es
	(a)	Cathine ((+)-norpseudoephedrine)	1230
	(b)	Diethylpropion	1610
	(c)	Fencamfamin	1760
	(d)	Fenproporex	1575
	(e)	Mazindol	1605
	(f)	Mefenorex	. 1580

	(g)	Modafinil	1680
	(h)	Pemoline (including organometallic complexes and chelates thereof)	1530
	(i)	Phentermine	1640
(j) (k)		Pipradol	.1750
		Sibutramine	1675
(1)	(1)	SPA ((-)-1-dimethylamino-1,2-diphenylethane)	1635
(7)	compo	substances. Unless specifically excepted or unless listed in another schedule, any und, mixture, or preparation which contains any quantity of the following substance its salts:	
	(a)	Pentazocine	9709
	(b)	Butorphanol (including its optical isomers)	9720
	(c)	Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and salts of isomers.	.9725

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.05 Controlled Substances in Schedule V.

- (1) Schedule V consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Narcotic drugs containing non-narcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:
 - (a) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
 - (b) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
 - (c) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
 - (d) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
 - (e) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
 - (f) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
- (3) Stimulants. Unless specifically exempted or excluded, or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers:

- (4) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances have a depressant effect on the central nervous system, including its salts:
 - (a) Brivaracetam ((2S)-2-[(4R)-2-oxo-4- propylpyrrolidin-1-yl] butanamide).....2710

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.06 Controlled Substances in Schedule VI.

- (1) Marijuana......7360
- (2) Tetrahydrocannabinols.......7370
- (3) Unless specifically excepted or unless listed in another schedule, synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity. Examples include the following drugs or their compounds regardless of numerical designation of atomic positions covered:
 - (a) 1 cis or trans tetrahydrocannabinol, and its optical isomers.
 - (b) 6 cis or trans tetrahydrocannabinol, and its optical isomers.
 - (c) 3, 4 cis or trans tetrahydrocannabinol, and its optical isomers.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.07 Controlled Substances in Schedule VII.

(1) Butyl nitrite and any isomer of butyl nitrite

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.08 Non-narcotic Substances Excluded from Controlled Substances

(1) Non-narcotic substances listed in the most current edition of 21 C.F.R. 1308.22, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.09 Chemical preparations excluded from Controlled Substances

(1) Chemical preparations listed in the most current edition of 21 C.F.R. 1308.24, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.10 Veterinary anabolic steroid implant products excluded from Controlled Substances.

(1) Veterinary anabolic steroid implant products listed in the most current edition of 21 C.F.R. 1308.26, are excluded from all schedules.

- Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.
- 0940-06-01-.11 Prescription products excluded from Controlled Substances
 - Prescription products listed in the most current edition of 21 C.F.R. 1308.32, are excluded from all schedules.
- Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.
- 0940-06-01-.12 Anabolic steroid products excluded from Controlled Substances
 - (1) Anabolic steroid products listed in the most current edition of 21 C.F.R. 1308.34, are excluded from all schedules.
- Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.
- 0940-06-01-.13 Certain cannabis plant material, and products made therefrom, excluded from Controlled Substances
 - (1) Certain cannabis plant material, and products made therefrom, that contain tetrahydrocannabinols listed in the most current edition of 21 C.F.R. 1308.35, are excluded from all schedules.

Authority: Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

* If a roll-call vote was necessary, the vote by the Agency on these rulemaking hearing rules was as follows:

Board Member	Aye	No	Abstain	Absent	Signature (if required)
and the second	11				

I certify that this is an accurate and complete copy of rulemaking hearing rules, lawfully promulgated and adopted by the <u>Tennessee Department of Mental Health and Substance Abuse Services</u> (board/commission/other authority) on <u>0 2/02/2017</u> (mm/dd/yyyy), and is in compliance with the provisions of T.C.A. § 4-5-222.

	0.7 (a) 120 (a)		
I fu	rther certify the following:		
Not	tice of Rulemaking Hearing filed	d with the Department of State on: (11/04/16)	
Rul	lemaking Hearing(s) Conducted	d on: (add more dates). (01/04/17)	
	STATE	Date: 2.2/17/	
	STATE OF TENNESSEE ** NOTARY PUBLIC ** ** ** ** ** ** ** ** ** ** ** ** **	Name of Officer: Marie Williams Commissioner, Tennessee Department of Mental Health	
	OF DAYION	Title of Officer: and Substance Abuse Services	
	Subscribe	ad and sworn to before me on:	
		Notary Public Signature: Sue B. Hund	
		My commission expires on:	
		May 0, 2017	•
	15	Date: 6 Feb 2017	



Subscribed and sworn to before me on:

Notary Public Signature:

My commission expires on:

Title of Officer: Commissioner, Tennessee Department of Health

Name of Officer: John J. Dreyzehner, MD, MPH

All rulemaking hearing rules provided for herein have been examined by the Attorney General and Reporter of the State of Tennessee and are approved as to legality pursuant to the provisions of the Administrative Procedures Act, Tennessee Code Annotated, Title 4, Chapter 5.

Herbert H. Slatery III Attorney General and Reporter

3/13/2017

Date

Department of State Use Only

Filed with the Department of State on

3/21/17

Effective on:

Tre Hargett Secretary of State

My Commission Expires
May 8, 2017



Public Hearing Comments

One copy of a document containing responses to comments made at the public hearing must accompany the filing pursuant to T.C.A. § 4-5-222. Agencies shall include only their responses to public hearing comments, which can be summarized. No letters of inquiry from parties questioning the rule will be accepted. When no comments are received at the public hearing, the agency need only draft a memorandum stating such and include it with the Rulemaking Hearing Rule filing. Minutes of the meeting will not be accepted. Transcripts are not acceptable

TDMHSAS Responses to Comments about
Rules Chapter 0940-06-01
Consideration of Chapter 0940-06-01 Controlled Substances
Rulemaking Hearing Held on January 4, 2017

*The Department has attempted to present the following comments in a form that is both easy to read and accurate to the intent of the commenter. In rare cases, the Department made technical edits to increase the readability of a comment. Please forgive any typographical errors in both the comments and responses.

JIMMY MUSICE, SENIOR POLICY ADVISOR AND ATTORNEY, TENNESSEE BUREAU OF INVESTIGATION: I'm here to let you know what our stance was and that was to recommend that etizolam be added to Schedule I in the rules. And I'm going to let Glenn Everitt give you an overview as to why we feel that way.

GLENN EVERITT, SUPERVISING SPECIAL AGENT FORENSIC SCIENTIST, TENNESSEE BUREAU OF INVESTIGATION: We've been monitoring etizolam for the past few years and it's exponentially grown over the years. We started out seeing it in 2014 and saw a few cases and then it grew from there. In 2015 we saw 29 cases and so far this year we've seen 94 cases. A lot of times we see etizolam in combination with Fentanyl and not that we don't see it as a powder by itself but we general see it in the fake Xanax tablets that mimic Alprazolam. There are different stamps they make for the tablets – the Xanax IIs or the GG2-49s. We've being seeing those and as far as I know the FDA does not have any use for that. I know that it has been used in other countries as a benzodiazepine but to my knowledge the FDA has not regulated that.

Mr. Musice: I would like to add that states surrounding Tennessee have scheduled it as a Schedule I – Alabama, Arkansas, Mississippi, Virginia and Florida. Most of those states did so in 2014 when they first began to see it. We've seen it used as a date-rape drug in the field. Glenn talked about some of the lab results going from 3 to 29 then to 94 but we've also see an increase on the toxicology side and that's when someone is pulled over for DUI and they may do a blood draw on them. In 2015 state-wide, 18 results contained etizolam and that was only used in the Middle District lab so it wasn't state-wide. But so far in 2016 state-wide it's up to 34. So, not only have we seen the increase through our drug agents purchasing and going after organizations but we're seeing it in the blood results of drivers, driving intoxicated on Tennessee roads.

Kurt Hippel: So you see an abuse potential for this substance?

Mr. Musice: Absolutely.

Mr. Everitt: Yes, definitely. As it stands now because our analogue law etizolam does not fit the legal definition of an analogue in the T.C.A. the way it's currently written it won't even though if you are asking me as a scientist is it an analogue, yes. Does it have the same affects as a benzodiazepine, yes. But as our law is currently written for the analogue, you can't make that jump to say that it's legally an analogue. So really there's no recourse to prosecute it. So therefore we're seeing it increasing every year.

Kurt Hippel: Dr. Geminn, do you have any questions?

Dr. Geminn: My question would be, with your agents in the field, what is the source? Because it's not approved for use in the United States so I assume it can't legally be imported.

Mr. Musice: Without getting too specific, there are ways throughout the Internet to obtain this substance and get it here, and get it here in bulk. I don't mean it's coming over in sandwich bags but full kilos being shipped here to Tennessee. What they do, they'll take that product add a binder and usually... (to **Glenn Everitt**) what else will they add to it when they're going to stamp the pill?

Dr. Geminn: Starch.

Mr. Everitt: Polymeric acid, uric acid, vositol, a number of things they can do.

Mr. Musice: But mainly, because right now etizolam is approved for use in Japan, India and Italy, we see more of Asian markets that are creating the etizolam. And like other drugs sometimes the Asians use the Mexican cartels as their distribution resource and a way to get it into the United States. But I didn't want to say that's the only way because like I said, you can order it off the Internet on certain websites.

Dr. Geminn: I don't know if you've researched it at all, but Georgia made it a Schedule IV which is with the other benzodiazepines. Do you have any idea why maybe that state made it a Schedule IV? Are there arguments for making it in any another Schedule than a Schedule I?

Mr. Musice: My assumption would be is that because it acts and mimics a benzodiazepine that they placed it in Schedule IV with all the other benzodiazepines. But our position would be that because the United States does not have a recognized reason for etizolam then that would put it in Schedule I with the others.

Dr. Geminn: That's all the questions I have.

Kurt Hippel: Great. Dr. Loyd?

Dr. Loyd: I want to follow up on Dr. Geminn's question. So, is this similar to what's happening with fentanyl right now?

Mr. Everitt: Yes, it can be. And we're often seeing it mixed with the fentanyl when creating counterfeit opioids.

Dr. Loyd: Okay, Thank you.

Kurt Hippel: Thank you. Does anyone else on the Department panel have a question for the TBI? Thank you Gentlemen, we will take these comments and recommendations under full consideration. That is the end of my list of people who would want to make comments today. I will look through the room one last time to make sure no one else wants to say anything.

Dr. Geminn: One more question for the TBI, I'll repeat their answer if they can't hear. Have there been any deaths associated with etizolam? Any like post mortem drug....

Mr. Everitt: Yes and No. Yes, because the deaths that we've seen, fentanyl or heroin...

Dr. Geminn: It's "with"

Mr. Everitt ... or any combination with etizolam. I'm sorry. I'm not sure....

Dr. Geminn: You can't say what the causative agent is but it's been associated in those screens for deceased individuals?

Mr. Everitt: Right. I don't know if etizolam acts like an antagonist to enhance the effects of the heroin or fentanyl. I'm not exactly sure as to why they are putting that in with heroin or fentanyl.

Kurt Hippel: But it is present in lab tests where someone has died?

Mr. Everitt: Correct

Dr. Geminn: Has overdosed?

Mr. Everitt: Yes.

Dr. Loyd: I think we make the assumption that it's a benzodiazepine or very close. So it potentiates the effect of the fentanyl. That's generally the cause. It's got a little bit different chemical structure; its half-life is a little longer too. Theoretically that makes it have a less potential for abuse, but I don't think that's what we are looking at here. We're looking at it as there being no medical valid reason to be used in the

United States, not FDA approved. And then also the potential toxicity.

TDMHSAS Response: After considering the information provided by the Tennessee Bureau of Investigation and pursuant to T.C.A. 39-17-403(a) & (b), the substance etizolam, also known as Etilaam, Etizola, Sedekopan, Pasaden, Depas, will be scheduled as a Schedule 1 controlled substance in this rule (TDMHSAS Rule Chapter 0940-06-01 Controlled Substances). The findings, as set out by T.C.A. 39-17-403(a), regarding the scheduling of etizolam as a Schedule 1 controlled substance are as follows:

1. The actual or relative potential for abuse:

Etizolam is a thienodiazepine which has a chemically related structure to a class of substances known as benzodiazepines. Benzodiazepines are widely prescribed drugs with a known abuse potential while etizolam currently does not have an accepted medical use in the United States. While etizolam does have a medically accepted use in a few international countries, it typically requires a prescription and is usually considered a controlled substance only when considering benzodiazepines as a whole. Due to etizolam being a benzodiazepine analog, it does have anxiolytic effects, but has a short duration of action which may lead to dependence.²

2. The scientific evidence of its pharmacological effect, if known:

Since etizolam is a benzodiazepine analog, it possesses anxiolytic, anticonvulsant, sedative-hypnotic, and muscle relaxant effects similar to other benzodiazepines.

3. The state of current scientific knowledge regarding the substance:

Etizolam was developed in Japan and is registered as a medicine in at least 3 countries: Japan, Italy, and India. The majority of current scientific knowledge regarding etizolam is due to the study of benzodiazepines as a whole.³

4. The history and current pattern of abuse:

Etizolam has a limited history of abuse due to lack of specific tracking through drug screens. According to the Tennessee Bureau of Investigation, drug screens showing positive for etizolam have been increasing, with 29 cases in 2015 and 94 cases in 2016.

5. The scope, duration and significance of abuse:

Etizolam is a benzodiazepine analog and has a generally similar pharmacological profile to the benzodiazepine class. Approximately 30% of the 1,045 deaths in 2015 caused by opioid overdose also involved benzodiazepine use in Tennessee. Tennessee's prescription drug overdose rate is 26% above the national average and Tennessee leads the nation in the number of controlled substance prescriptions per capita.

6. The risk to the public health:

Benzodiazepines and analogs such as etizolam may be abused or may be used in combination with other drugs of abuse to produce additive results. Etizolam is also not currently classified as a controlled substance, which poses a threat to public safety since prosecutors are unable to prosecute anyone with possession or intention for distribution of this compound.

7. The potential of the substance to produce psychic or physiological dependence liability:

In animal experiments, etizolam has been shown to be approximately 10 times more potent than diazepam (Valium®). Dependence may develop with regular use of benzodiazepines, which may precipitate withdrawal syndrome when the drug is discontinued.

8. Whether the substance is an immediate precursor of a substance already controlled under this section:

This substance is not an immediate precursor of a substance already controlled in Tennessee. Although this is an analog, the chemical structure of etizolam does not put it under our previous actions for controlling analogs and precursors to controlled substances.

¹ Drug and Chemical Evaluation Section: Etizolam. (Oct 2014). Office of Diversion Control, Drug Enforcement Administration, Retrieved January 5, 2017 from https://www.deadiversion.usdoj.gov/drug_chem_info/etizolam.pdf

^{2,3} Gupta, S., & Garg, B. (2014). A case of etizolam dependence. Indian Journal of Pharmacology, 46(6), 655–656. http://doi.org/10.4103/0253-7613.144943

Regulatory Flexibility Addendum

Pursuant to T.C.A. §§ 4-5-401 through 4-5-404, prior to initiating the rule making process, all agencies shall conduct a review of whether a proposed rule or rule affects small business.

These rules will not affect small businesses. Although, some pharmacies qualify as small businesses, the changes to the controlled substances schedules promulgated by these rules should not change the daily operations of those pharmacies.

Economic Impact Statement

1) The type or types of small business and an identification and estimate of the number of small businesses subject to the proposed rule that would bear the cost of, or directly benefit from the proposed rule.

These rules will not affect small businesses.

2) The projected reporting, recordkeeping and other administrative costs required for compliance with the proposed rule, including the type of professional skills necessary for preparation of the report or record.

These rules will not affect reporting, recordkeeping, or other administrative costs of small businesses.

3) A statement of the probable effect on impacted small businesses and consumers.

These rules will not affect small businesses.

4) A description of any less burdensome, less intrusive or less costly alternative methods of achieving the purpose and objectives of the proposed rule that may exist, and to what extent the alternative means might be less burdensome to small business.

There is no less burdensome, less intrusive or less costly alternative methods of achieving the purpose and objectives of the proposed rules.

5) A comparison of the proposed rule with any federal or state counterparts.

These rules compare favorably with the federal controlled substances schedules as T.C.A. § 39-17-403 requires the Tennessee Department of Mental Health and Substance Abuse Services (TDMHSAS) to schedule substances if those substances have been designated as controlled substances by federal regulations promulgated by the U.S. Department of Justice Drug Enforcement Administration (DEA), unless TDMHSAS, upon agreement with the Tennessee Department of Health (TDH), decides otherwise.

6) Analysis of the effect of the possible exemption of small businesses from all or any part of the requirements contained in the proposed rule.

These rules will not affect small businesses.

Impact on Local Governments

Pursuant to T.C.A. §§ 4-5-220 and 4-5-228 "any rule proposed to be promulgated shall state in a simple declarative sentence, without additional comments on the merits of the policy of the rules or regulation, whether the rule or regulation may have a projected impact on local governments." (See Public Chapter Number 1070 (http://state.tn.us/sos/acts/106/pub/pc1070.pdf) of the 2010 Session of the General Assembly)

TDMHSAS estimates that these rules will not have a projected financial impact on local governments.

Additional Information Required by Joint Government Operations Committee

All agencies, upon filing a rule, must also submit the following pursuant to T.C.A. § 4-5-226(i)(1).

(A) A brief summary of the rule and a description of all relevant changes in previous regulations effectuated by such rule;

The lists of controlled substances for all schedules were revised to ensure consistency with Part 1308 of Title 21 of the Code of Federal Regulations (C.F.R.) and T.C.A. §§ 39-17-406, 39-17-408, 39-17-410, 39-17-412, 39-17-414, and 39-17-416.

0940-06-01-.01 names controlled substances within Schedule I including opiates, opium derivatives, hallucinogenic substances, depressants, and stimulants. Etizolam, although not federally scheduled, has been scheduled as a Schedule I controlled substance in this rule (see TDMHSAS Findings on p. 29 of this document). 0940-06-01-.02 names controlled substances within Schedule II including opium and opiates, substances produced by extraction from vegetable origin or chemical synthesis, opiates, stimulants, depressants, hallucinogenic substances, immediate precursors to amphetamine and methamphetamine, and PCP. 0940-06-01-.03 names controlled substances within Schedule III including stimulants, depressants, nalorphine, narcotic drugs, anabolic steroids, and hallucinogenic substances.

0940-06-01-.04 names controlled substances within Schedule IV including narcotic drugs, depressants, fenfluramine, and stimulants.

0940-06-01-.05 names controlled substances within Schedule V including narcotic drugs containing non-narcotic active medicinal ingredients, stimulants, and depressants.

0940-06-01-.06 names controlled substances within Schedule VI including marijuana and tetrahydrocannabinols.

0940-06-01-.07 names controlled substances within Schedule VII including butyl nitrite and any isomer of butyl nitrite.

0940-06-01-.08 incorporates by reference exclusions for non-narcotic substances listed in the most current edition of 21 C.F.R. 1308.22 including those sold lawfully over the counter without a prescription.

0940-06-01-.09 names chemical preparations excluded from controlled substances.

0940-06-01-.10 names veterinary anabolic steroid implant products excluded from controlled substances.

0940-06-01-.11 names prescription products excluded from controlled substances.

0940-06-01-.12 names anabolic steroid products excluded from controlled substances.

0940-06-01-.13 names certain cannabis plant material, and product made therefrom, excluded from controlled substances.

- **(B)** A citation to and brief description of any federal law or regulation or any state law or regulation mandating promulgation of such rule or establishing guidelines relevant thereto;
- 21 U.S.C. 812: Establishes schedules of controlled substances.
- 21 C.F.R. 1308: Contains schedules of controlled substances set forth by the U.S. Department of Justice Drug Enforcement Administration.
- T.C.A. § 4-4-103: Empowers the Commissioner of each department to prescribe regulations.
- T.C.A. § 33-1-302: Empowers the Department to make and enforce rules necessary for the efficient financial management and lawful operation of facilities and services.
- T.C.A. § 33-1-303: Defines powers of the Commissioner including rulemaking authority.
- T.C.A. § 33-1-305: Empowers the Commissioner of the Department of Mental Health and Substance Abuse Services to adopt rules to fulfill the Department's responsibilities.
- T.C.A. § 33-1-309: Requires the Department to adopt all rules in accordance with the Uniform Administrative Procedures Act.
- T.C.A. § 39-17-403: Requires the Commissioner of the Department of Mental Health and Substance Abuse Services, upon agreement of the Commissioner of the Department of Health, to control substances according to certain guidelines.
- (C) Identification of persons, organizations, corporations or governmental entities most directly affected by this rule, and whether those persons, organizations, corporations or governmental entities urge adoption or rejection of this rule;

This rule affects healthcare professionals and pharmacies; as well as the TN Boards of Nursing, Medical Examiners, and Pharmacy; the TennCare Inspector General and the TN Bureau of Investigation. The Department received comments from the TN Bureau of Investigation regarding this rule during the rulemaking

hearing held for this rule on January 4th, 2017. These were the only comments received regarding this rule and TDMHSAS adopted the action proposed by the comments from the TN Bureau of Investigation.

(D) Identification of any opinions of the attorney general and reporter or any judicial ruling that directly relates to the rule or the necessity to promulgate the rule;

There are no opinions of the Attorney General and Reporter that directly relate to these rules.

(E) An estimate of the probable increase or decrease in state and local government revenues and expenditures, if any, resulting from the promulgation of this rule, and assumptions and reasoning upon which the estimate is based. An agency shall not state that the fiscal impact is minimal if the fiscal impact is more than two percent (2%) of the agency's annual budget or five hundred thousand dollars (\$500,000), whichever is less;

It is estimated that these rules will not have a fiscal impact on state and local government revenues and expenditures.

(F) Identification of the appropriate agency representative or representatives, possessing substantial knowledge and understanding of the rule;

Wesley Geminn, Chief Pharmacist, TDMHSAS Kurt Hippel, Director of Legislation, Rules & Privacy, TDMHSAS

(G) Identification of the appropriate agency representative or representatives who will explain the rule at a scheduled meeting of the committees;

Wesley Geminn, Chief Pharmacist, TDMHSAS Kurt Hippel, Director of Legislation, Rules & Privacy, TDMHSAS

(H) Office address, telephone number, and email address of the agency representative or representatives who will explain the rule at a scheduled meeting of the committees; and

Wesley Geminn, Chief Pharmacist
Tennessee Department of Mental Health and Substance Abuse Services
6th Floor, Andrew Jackson Building
500 Deaderick Street
Nashville, TN 37243
Wesley.Geminn@tn.gov
615-532-6736

Kurt Hippel, Director of Legislation, Rules & Privacy
Tennessee Department of Mental Health and Substance Abuse Services
5th Floor, Andrew Jackson Building
500 Deaderick Street
Nashville, TN 37243
Kurt.Hippel@tn.gov
615-532-9439

(I) Any additional information relevant to the rule proposed for continuation that the committee requests.

N/A

Department of State Division of Publications 312 Rosa L. Parks Avenue, 8th Floor Snodgrass/TN Tower Nashville, TN 37243 Phone: 615-741-2650

Email: publications.information@tn.gov

For Department of St	ate Use Only
Sequence Number:	
Rule ID(s):	
File Date:	
Effective Date:	

Rulemaking Hearing Rule(s) Filing Form

Rulemaking Hearing Rules are rules filed after and as a result of a rulemaking hearing (Tenn. Code Ann. § 4-5-205).

Pursuant to Tenn. Code Ann. § 4-5-229, any new fee or fee increase promulgated by state agency rule shall take effect on July 1, following the expiration of the ninety (90) day period as provided in § 4-5-207. This section shall not apply to rules that implement new fees or fee increases that are promulgated as emergency rules pursuant to § 4-5-208(a) and to subsequent rules that make permanent such emergency rules, as amended during the rulemaking process. In addition, this section shall not apply to state agencies that did not, during the preceding two (2) fiscal years, collect fees in an amount sufficient to pay the cost of operating the board, commission or entity in accordance with § 4-29-121(b).

Agency/Board/Commission:	Tennessee Department of Mental Health and Substance Abuse Services
Division:	Division of Substance Abuse Services
Contact Person:	Kurt Hippel, Office of Legislation, Rules & Privacy
Address:	500 Deaderick Street, 5th Floor, Andrew Jackson Building
	37243
Phone:	615-532-6520
Email:	Kurt.Hippel@tn.gov

Revision Type (check all that apply):

Amendment

X New

X Repeal

Rule(s) (ALL chapters and rules contained in filing must be listed here. If needed, copy and paste additional tables to accommodate multiple chapters. Please make sure that ALL new rule and repealed rule numbers are listed in the chart below. Please enter only ONE Rule Number/Rule Title per row)

Chapter Number	Chapter Title
0940-06-01	Controlled Substances
Rule Number	Rule Title
0940-06-0101	Controlled Substances in Schedule I
0940-06-0102	Controlled Substances in Schedule II
0940-06-0103	Controlled Substances in Schedule III
0940-06-0104	Controlled Substances in Schedule IV
0940-06-0105	Controlled Substances in Schedule V
0940-06-0106	Controlled Substances in Schedule VI
0940-06-0107	Controlled Substances in Schedule VII
0940-06-0108	Non-Narcotic Substances Excluded from Controlled Substances
0940-06-0109	Chemical preparations excluded from Controlled Substances
0940-06-0110	Veterinary anabolic steroid implant products excluded from Controlled Substances
0940-06-0111	Prescription products excluded from Controlled Substances
0940-06-0112	Anabolic steroid products excluded from Controlled Substances
0940-06-0113	Certain cannabis plant material, and products made therefrom, excluded from Controlled Substances

(Place substance of rules and other info here. Please be sure to include a detailed explanation of the changes being made to the listed rule(s). Statutory authority must be given for each rule change. For information on formatting rules go to http://sos.tn.gov/sites/default/files/forms/Rulemaking Guidelines August2014.pdf)

Chapter 0940-06-01 Controlled Substances

Chapter 0940-06-01 Controlled Substances is being repealed and rewritten including its table of contents.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-305, 33-1-309, and 39-17-403

Chapter 0940-06-01 Controlled Substances

New Rule

0940-06-01-.01 Controlled Substances in Schedule I.

- (1) Schedule I consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation. For the purposes of subparagraph (II) 3-Methylfentanyl, only, the term isomer includes the optical and geometric isomers.

	(a)	Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidnyl]-N-phenyl-acetamide)	9815
	(b)	Acetylfentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide)	9821
	(c)	Acetylmethadol	9601
	(d)	Allylprodine	9602
	(e)	Alphacetylmethadol (except levo-alphacetylmethadol also known as levo-alpha-acetylmethadol; levomethadyl acetate; or LAAM)	9603
Aa.	(f)	Alphameprodine	9604
	(g)	Alphamethadol	9605
	(h)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionan 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine)	
	(i)	Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)	9832
	(j)	Benzethidine	9606
	(k)	Betacetylmethadol	9607
	(I)	Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)	9830

(m)	Beta-hydroxythiofentanyl	9836
	Other name: N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phe N-[1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide	nylpropionamid
(<u>n</u> m)	Beta-hydroxy-3-methylfentanyl	0024
(<u>11</u> +++)	Other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phe	
(<u>o</u> n)	Betameprodine	9608
(<u>p</u> e)	Betamethadol	9609
(<u>qp</u>)	Betaprodine	
<u>(r)</u>	Butyryl Fentanyl	9822
	Other name: N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, N-(1-phenylbutanamide)	<u>enethylpiperidin</u>
(<u>s</u> q)	Clonitazene	9612
(<u>t</u> r)	Diampromide	9613
(<u>u</u> s)	Dampromac	
(<u>∨</u> ŧ)	Diethylthiambutene	9616
(<u>w</u> u)	Difenoxin	9168
(<u>×</u> ¥)	Dimenoxadol	
(Σ ₩)	Dimepheptanol	
(<u>z</u> ×)	Dimethylthiambutene	
(<u>aa</u> y)	Dioxaphetyl butyrate	
(<u>bb</u> z)	Dipipanone	
(<u>cc</u> aa)	Ethylmethylthiambutene	
(ddbb)	Etonitazene	9624
(<u>ee</u> ee)	Etoxeridine	9625
(ffdd)	Furethidine	9626
<u>(gg)</u>	Furanyl Fentanyl	9834

(<u>hh</u> ee)	Hydroxypethidine	9627
(<u>ii</u> ff)	Ketobemidone	9628
(jigg)	Levomoramide	9629
(<u>kk</u> hh)	Levophenacylmorphan	9631
(<u> </u> ii)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide).	9813

(<u>mm</u> jj)	3-Methylthiotentanyi (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)	. 9833
(<u>nn</u> kk)	Morpheridine	9632
(<u>oo</u> ll)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	9661
(ppmm) Noracymethadol	9633
(<u>qq</u> nn)	Norlevorphanol	9634
(<u>rr</u> ee)	Normethadone	. 9635
(sspp)	Norpipanone	
(<u>tt</u> qq)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]	
	propanamide)	W
(<u>uu</u> ff)	PEPAP (1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine)	9663
(<u>vv</u> ee)	Phenadoxone	9637
(<u>ww</u> tt)	Phenampromide	
(<u>xx</u> uu)	Phenomorphan	
(<u>yy</u> vv)	Phenoperidine	
(<u>zz</u> ww)	Piritramide	9642
(<u>aaa</u> xx)	Proheptazine	9643
(<u>bbbyy</u>)	Properidine	9644
	Propiram	
(<u>ddd</u> aa	a)	Racem
14	oramide	9645
(eeebbl	e)	Thiofen
	tanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide)	9835
(fffece)	Tilidine	9750
(gggddd	d)Trimeperidine	9646
(hhh)	U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide	9547
All .		
followin	derivatives. Unless specifically excepted or unless listed in another schedule, any g opium derivatives, its salts, isomers, and salts of isomers, whenever the existen lts, isomers, and salts of isomers is possible within the specific chemical designat	ce of
(a)	Acetorphine	9319
(b)	Acetyldihydrocodeine	9051

(3)

	(c)	Benzylmorphine	9052
	(d)	Codeine methylbromide	9070
	(e)	Codeine-N-Oxide	9053
	(f)	Cyprenorphine	9054
	(g)	Desomorphine	9055
	(h)	Dihydromorphine	9145
	(i)	Drotebanol	9335
	(j)	Etorphine (except hydrochloride salt)	9056
	(k)	Heroin	9200
	(I)	Hydromorphinol	
	(m)	Methyldesorphine	9302
	(n)	Methyldihydromorphine	9304
	(o)	Morphine methylbromide	9305
	(p)	Morphine methylsulfonate	9306
	(q)	Morphine-N-Oxide	9307
	(r)	Myrophine	
	(s)	Nicocodeine	9309
	(t)	Nicomorphine	9312
	(u)	Normorphine	9313
	(v)	Pholcodine	9314
	(w)	Thebacon	9315
(4)	materia hallucin whenev specifie	nogenic substances. Unless specifically excepted or unless listed in another schedul, compound mixture, or preparation, which contains any quantity of the following nogenic substances, or which contains any of its salts, isomers, and salts of isomers wer the existence of such salts, isomers, and salts of isomers, is possible within the ed chemical designation (for purposes of this paragraph only, the term "isomer" included, position and geometric isomers):	S
	(a)	Alpha-ethyltryptamine	7249
	(b)	Alpha-methyltryptamine Other name: AMT	7432
	(c)	4-Bromo-2,5-dimethoxyamphetamine	
	(d)	4-Bromo-2,5-dimethoxyphenethylamine	7392
SS-7039 (June 20	016)	RDA 16	93

	Other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B; Nexus
(e)	2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(f)	Bufotenine
(g)	2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(h)	Diethyltryptamine
(i)	2,5-Dimethoxyamphetamine
(j)	2, 5-Dimethoxy-4-ethylamphetamine
(k)	2, 5 Dimethoxy-4-(n)-propylthiophenethylamine
(1)	Dimethyltryptamine
(m)	Ethylamine analog of phencyclidine
(n)	Ibogaine
(o)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
(p)	Lysergic acid diethylamide
(q)	Mescaline
(r)	4-Methoxyamphetamine
(s)	5-Methoxy-3,4-methylenedioxyamphetamine
(t)	5-Methoxy-N,N-diisopropyltryptamine
(u)	5-methoxy-N,N-dimethyltryptamine
(v)	4-Methyl-2, 5-dimethoxyamphetamine

(w)	3,4-Methylenedioxyamphetamine)
(x)	3,4-Methylenedioxymethamphetamine	ľ
(y)	3,4-Methylenedioxy-N-ethylamphetamine	
(z)	3,4-Methylenedioxy-N-methylcathinone	
(aa)	N-Ethyl-3-piperidyl benzilate	
(bb)	N-Hydroxy-3,4-methylenedioxyamphetamine	(y
(cc)	N-methyl-3-piperidyl benzilate	
(dd)	Parahexyl	
(ee)	Peyote	Ĺ
(ff)	Psilocybin (constituent of magic mushrooms)	ļ
(gg)	Psilocyn (constituent of magic mushrooms)	ŀ
(gg) (hh)	Psilocyn (constituent of magic mushrooms)	
	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine)	
(hh)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine)	
(hh)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine)	1
(hh) (ii) (jj)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine)	
(hh) (ii) (jj) (kk)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine). 7458 Other names: PCPy; PHP 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine. 7473 Other names: TCPy 4- Methylmethcathinone 1248 Other names: mephedrone; methpadrone; 4-MMC 3,4-Methylenedioxypyrovalerone 7535 Other names: MDPV	
(hh) (ii) (jj) (kk) (ll)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine). 7458 Other names: PCPy; PHP 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine. 7473 Other names: TCPy 4- Methylmethcathinone 1248 Other names: mephedrone; methpadrone; 4-MMC 3,4-Methylenedioxypyrovalerone 7535 Other names: MDPV 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 7509	
(hh) (ii) (jj) (kk) (il) (mm)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine). 7458 Other names: PCPy; PHP 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine. 7473 Other names: TCPy 4- Methylmethcathinone 1248 Other names: mephedrone; methpadrone; 4-MMC 3,4-Methylenedioxypyrovalerone 7535 Other names: MDPV 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 7509	
(hh) (ii) (jj) (kk) (ll) (mm) (nn)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine). 7458 Other names: PCPy; PHP 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine. 7473 Other names: TCPy 4- Methylmethcathinone. 1248 Other names: mephedrone; methpadrone; 4-MMC 3,4-Methylenedioxypyrovalerone. 7535 Other names: MDPV 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E). 7509 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D). 7508 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C). 7519	
(hh) (ii) (jj) (kk) (il) (mm) (nn) (oo)	Pyrrolidine analog of phencyclidine (1-(1-phenylcyclohexyl)-pyrrolidine). 7458 Other names: PCPy; PHP 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine. 7473 Other names: TCPy 4- Methylmethcathinone 1248 Other names: mephedrone; methpadrone; 4-MMC 3,4-Methylenedioxypyrovalerone. 7535 Other names: MDPV 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E). 7509 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D). 7508 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C). 7519 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine (2C-I). 7518	

	(ss)	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)
	(tt)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)
	(uu)	Thiophene analog of phencyclidine
	(vv)	3,4,5-Trimethoxyamphetamine
	(ww)	(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
	(xx)	1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 7011 Other names: 5-fluoro-UR-144; 5-F-UR-144; XLR11; 1-(5-fluoro-pentyl)-3-(2,2,3,3-tetramethylcyclopropoyl)indole
(5)	comport having isomers	sants. Unless specifically excepted or unless listed in another schedule, any material, und, mixture, or preparation which contains any quantity of the following substances a depressant effect on the central nervous system, including its salts, isomers, and salts of swhenever the existence of such salts, isomers, and salts of isomers is possible within the ed chemical designation:
	<u>(a)</u>	Etizolam Other names; Etilaam, Etizola, Sedekopan, Pasaden, Depas
	(ba)	Gamma-hydroxybutyric acid
	(<u>c</u> b)	Mecloqualone 2572
	(<u>d</u> e)	Methaqualone
(6)	compo	
Cierovia	(a)	Alpha-pyrrolidinobutiophenone
	(6)	Alpha-pyrrolidinopentiophenone
	(b)	Other names: [alpha]-PVP; [alpha]-pyrrolidinovalerophenone; 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one
	(c)	Aminorex
	(d)	Butylone
	(e)	Cathinone
	(f)	3-Fluoro-N-methylcathinone

(g)	4-Fluoro-N-methylcathinone. Other names: 4-FMC; flephedrone; 1-(4-fluorophenyl)-2-(methylamino)propan-1-0	
(h)	Fenethylline	.1503
(i)	Methcathinone	one;
(j)	(+/-) cis-4-Methylaminorex (cis isomer) Other name: (+/-)cis-4,5 dihydro-4-methyl-5-phenyl-2-oxazolamine	1590
(k)	4-Methyl-N-ethylcathinone Other names: 4-MEC; 2-(ethylamino)-1-(4-methylphenyl)propan-1-one	1249
(1)	4-Methyl-alpha-pyrrolidinopropiophenone	7498 4-
(m)	Naphyrone Other names: naphthylpyrovalerone; 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan	1258 -1-one
(n)	N-Benzylpiperazine Other names: BZP; 1-benzylpiperazine	7493
(o)	N-Ethylamphetamine	1475
(p)	N,N-DimethylamphetamineOther names: N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenethylamine	1480
(q)	Pentedrone, Other names: [alpha]-methylaminovalerophenone; 2-(methylamino)-1-phenylpentone	1246 an-1-
(r)	Pentylone Other names: bk-MBDP; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one	7542
materia substar	pimimetic agents. Unless specifically exempted or unless listed in another schedule I, compound, mixture, or preparation which contains any quantity of the following nces, or which contains their salts, isomers, and salts of isomers whenever the exist salts, isomers, and salts of isomers is possible within the specific chemical design	stence
(a)	5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497)	7297
(b)	5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexal CP-47,497 C8-homolog)	nol or 7298
(c)	1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)	7118
(d)	1-Butyl-3-(1-naphthoyl)indole (JWH-073)	7173
(e)	1-Hexyl-3-(1-naphthoyl)indole (JWH-019)	7019
(f)	1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)	7200
(g)	1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)	6250

(h)	1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)	7081
(i)	1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)	7122
(j)	1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)	7398
(k)	(1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalen-1-yl)methanone (THJ-2201)	7024
(l)	1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)	7201
(m)	1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)	7694
(n)	1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19 and RCS-4)	
(0)	1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8)	7008
(p)	1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)	7203
(q)	N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamideOther names: APINACA; AKB48	7048
(r)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide Other names: AB-FUBINACA	7012
(s)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3-carboxamide Other names: AB-CHMINACA	.7031
(t)	N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide Other names: ADB-PINACA	7035
(u)	N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide Other names: AB-PINACA	7023
(v)	Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	.7225
(w)	Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate Other names: PB-22; QUPIC	7222

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.02 Controlled Substances in Schedule II.

- (1) Schedule II consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:
 - (a) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, thebaine-derived butorphanol, nalmefene, nalbuphine, naloxone, and naltrexone, and their respective salts, but including the following:

1.	Codeine	9050
2.	Dihydroetorphine	
3.	Ethylmorphine	9190
4.	Etorphine hydrochloride	9059
5.	Granulated opium	9640
6.	Hydrocodone	
7.	Hydromorphone	
8.	Metopon	9260
9.	Morphine	9300
10.	Opium extracts	9610
11,	Opium fluid	
12.	Oripavine	9330
13.		
14.	Oxymorphone	9652
15.	200 200000000	9639
16.	Raw opium	9600
17.	Thebaine	9333
18.	Tincture of opium	9630
Any sa	It, compound, derivative, or pre	paration thereof which is chemically equivalent or

- (b) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (2)(a) of this rule, except that these substances shall not include the isoguinoline alkaloids of opium.
- (c) Opium poppy and poppy straw.
- (d) Coca leaves (9040) and any salt, compound, derivative or preparation of coca leaves (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.
- (e) Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy)..... 9670
- Opiates. Unless specifically excepted or unless in another schedule any of the following opiates, including its isomers, esters, ethers, salts and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:

(a)	Alfentanil	9737
(b)	Alphaprodine	9010

SS-7039 (June 2016)

RDA 1693

(c)	Anileridine	9020
(d)	Bezitramide	9800
(e)	Carfentanil	. 9743
(f)	Dextropropoxyphene (bulk, non dosage forms)	9273
(g)	Dihydrocodeine	9120
(h)	Diphenoxylate	9170
(i)	Fentanyl	9801
(j)	Isomethadone	9226
(k)	Levo-alphacetylmethadol Other names: levo-alpha-acetylmethadol; levomethadyl acetate; LAAM	899000
(l)	Levomethorphan	
(m)	Levorphanol	
(n)	Metazocine	. 9240
(o)	Methadone	9250
(p)	Methadone-Intermediate; 4-cyano-2-dimethylamino-4,4-diphenyl butane	. 9254
(q)	Moramide-Intermediate; 2-methyl-3-morpholino-1,1-diphenylpropane-caboxylic acid	. 9802
(r)	Pethidine (meperidine)	9230
(s)	Pethidine-Intermediate-A; 4-cyano-1-methyl-4-phenylpiperidine	. 9232
(t)	Pethidine-Intermediate-B; ethyl-4-phenylpiperidine-4-carboxylate	. 9233
(u)	Pethidine-Intermediate-C; 1-methyl-4-phenylpiperidine-4-carboxylic acid	. 9234
(v)	Phenazocine	. 9715
(w)	Piminodine	9730
(x)	Racemethorphan	9732
(y)	Racemorphan	9733
(z)	Remifentanil	. 9739
(aa)	Sufentanil	. 9740
(bb)	Tapentadol	9780
(cc)	Thiafentanil	9729

⁽⁴⁾ Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

	(a)	Amphetamine, its salts, optical isomers, and salts of its optical isomers	1100
	(b)	Methamphetamine, its salts, isomers, and salts of its isomers	., 1105
	(c)	Phenmetrazine and its salts	1631
	(d)	Methylphenidate	1724
	(e)	Lisdexamfetamine, its salts, isomers, and salts of its isomers	1205
(5)	compo having isome	ssants. Unless specifically excepted or unless listed in another schedule any mater ound, mixture, or preparation which contains any quantity of the following substance of a depressant effect on the central nervous system, including its salts, isomers, a rs whenever the existence of such salts, isomers, and salts of isomers is possible ic chemical designation:	ces nd salts of within the
	(a)	Amobarbital	
	(b)	Glutethimide	2550
	(c)	Pentobarbital	
	(d)	Phencyclidine	
	(e)	Secobarbital	2315
(6)	Halluc	inogenic substances.	
	(a)	Nabilone. Other names: (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hy6-dimethyl-9H-dibenzo[b;d]pyran-9-one.	
(7)		diate precursors. Unless specifically excepted or unless listed in another schedule al, compound, mixture or preparation which contains any quantity of the following ances:	any
	(a)	Immediate precursor to amphetamine and methamphetamine:	
		1. Phenylacetone	8501
		Other names: phenyl-2-propanone; P2P; benzyl methyl ketone; methyl ketone;	oenzyl
	(b)	Immediate precursors to phencyclidine (PCP):	
		1. 1-phenylcyclohexylamine	7460
		2. 1-piperidinocyclohexanecarbonitrile(PCC)	. 8603
	(c)	Immediate precursor to fentanyl:	
		1. 4-anilino-N-phenethyl-4-piperidine (ANPP)	8333
Authority: T.C.	A. §§ 4-4	4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.	
0940-06-0103	3 Contro	olled Substances in Schedule III.	

SS-7039 (June 2016) RDA 1693

(1)

Schedule III consists of the drugs and other substances by whatever official name, common or

usual name, chemical name, or brand name designated, listed in this rule. Each drug or

substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.

- (2)Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric), and salts of such isomers whenever the existence of such salts. isomers, and salts of isomers is possible within the specific chemical designation:
 - (a) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under 21 C.F.R. 1308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled

(b) Benzphetamine		1228
-------------------	--	------

- (c)
- (d)
- Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances
- Any compound, mixture, or preparation containing: (a)

having a depressant effect in the central nervous system:

- Amobarbital 2126 1. Secobarbital 2316 2. 3.
 - Or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.
- (b) Any suppository dosage form containing:
 - Amobarbital 2126 1. 2. Secobarbital......2316 3. Pentobarbital 2271
- Or any salt of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.
- Any substance which contains any quantity of a derivative of barbituric acid or any salt (c)
 - 1.
 - Butabarbital (secbutabarbital)......2100 2.

- 4.
- 5.

3.

(e)

(3)

		6.	I niamyiai
ě.		7.	Thiopental2100
		8.	Vinbarbital2100
	(d)	Chlorh	exadol2510
	(e)	Embut	ramide
	(f)	hydrox applica codified	a hydroxybutyric acid preparations. Any drug product containing gamma ybutyric acid, including its salts, isomers, and salts of isomers, for which an tion is approved under § 505 of the federal Food, Drug, and Cosmetic Act, d in 21 U.S.C. § 301, et
	13		
	(g)		ne, its salts, isomers, and salts of isomers
	(h)		ic acid
	(i)	Lysergi	ic acid amide
	(j)	Methyp	prylon
	(k)	Peramı	panel, and its salts, isomers, and salts of isomers
	(l)	Sulfond	diethylmethane
	(m)	Sulfone	ethylmethane
	(n)	Sulfonr	nethane
	(0)	Tiletam	nine and zolazepam or any salt of tiletamine or zolazepam
	M	1.	Other name for a tiletamine-zolazepam combination product: Telazol®;
	de la company	2.	Other name for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
		3.	Other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo[3,4-e],[1,4]-diazepin-7(1H)-one; flupyrazapon
4)	Nalorph	nine	9400
5)	Narcoti	c Drugs.	
2	(a)	compo	specifically excepted or unless listed in another schedule, any material, und, mixture, or preparation containing any of the following narcotic drugs, or the alculated as the free anhydrous base or alkaloid, in limited quantities as set forth
		1	Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium9803
		2.	Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts

		3.	Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit with one or more active non-narcotic ingredients in recognized therapeutic amount
		4.	Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit with one or more active non-narcotic ingredients in recognized therapeutic amounts9808
		5.	Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts
		6.	Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, non-narcotic ingredients in recognized therapeutic amounts
	(b)		aterial, compound, mixture, or preparation containing any of the following narcotic or their salts:
4		1.	Buprenorphine
(6)	materia	al, compo	ds. Unless specifically excepted or unless listed in another schedule, any bund, mixture, or preparation containing any quantity of the following substances, ts, esters and ethers:
	(a)	Anaboli	ic steroids
		1.	3[alpha],17[beta]-dihydroxy-5a-androstane
		2.	17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane
		3.	17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5a-androstane
		4.	17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene
		5.	17[alpha]-methyl-[delta]1-dihydrotestosterone(17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one Other Names: 17-[alpha]-methyl-1-testosterone
		6.	17[alpha]-methyl-4-hydroxynandrolone(17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one)
		7.	1-Androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene)
		8.	1-Androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene)
		9.	4-Androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene)
	7/	10.	5-Androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene)
		11.	1-Androstenedione (5[alpha]-androst-1-en-3,17-dione)
		12.	4-Androstenedione (androst-4-en-3,17-dione)
		13.	5-Androstenedione (androst-5-en-3,17-dione)
		14.	3[Beta],17[Beta]-dihydroxy-5a-androstane
		15.	13[Beta]-ethyl-17[beta]-hydroxygon-4-en-3-one

- 16. Androstanedione (5[alpha]-androstan-3,17-dione)
- 17. Bolasterone (7[alpha], 17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one)
- 18. Boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one)
- 19. Boldione (androsta-1,4-diene-3,17-dione)
- 20. Calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one)
- Clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one)
 Other Names: 4-Chlorotestosterone
- Dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]methylandrost-1,4-dien-3-one)
- 23. [Delta]1-dihydrotestosterone (a.k.a.'1-testosterone') (17[Beta]-hydroxy-5[alpha]-androst-1-en-3-one)
- 24. Desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[Beta]-ol)
 Other name: madol
- 25. 4-Dihydrotestosterone (17[beta]-hydroxyandrostan-3-one)
- 26. Drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one)
- 27. Ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene)
- 28. Fluoxymesterone (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one)
- 29. Formebolone (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one)
- 30. Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)
- 31. 4-Hydroxy-19-nortestosterone (4.17[beta]-dihydroxyestr-4-en-3-one)
- 32 4-Hydroxytestosterone (4,17[beta]-dihydroxyandrost- 4-en-3-one)
- 33. Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one)
- 34. Mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one)
- 35. Methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-diene-3-one)
- Methandranone
- 37. Methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene)
- 38. Methandrostenolone
- 39. Methasterone (2[alpha],17[alpha]-dimethyl-5[alpha]-androstan-17[beta]-ol-3-one)
- 40. Methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one)
- 41. Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one)
- 42. Methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one)

- 43. Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4, 9,11-trien-3-one)
- 44. Mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one)
- 45. Nandrolone (17[beta]-hydroxyestr-4-en-3-one)
- 46. 19-Nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione)
- 47. 19-Nor-4-androstenediol (3[alpha],17[beta]-dihydroxyestr-4-ene)
- 48. 19-Nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene)
- 19-Nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene)
- 50. 19-Nor-5-androstenediol (3[beta],17[beta]-dihydroxyestr-5-ene)
- 51. 19-Nor-4-androstenedione (estr-4-en-3,17-dione)
- 52. 19-Nor-5-androstenedione (estr-5-en-3,17-dione)
- 53. Norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one)
- 54. Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one)
- 55. Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one)
- 56. Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one)
- 57. Oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one)
- 58. Oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one)
- 59. Oxymetholone (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-[5[alpha]]-androstan-3-one)
- 60. Prostanozol (17[beta]-hydroxy-5[alpha]-androstano[3,2-c]pryazole)
- 61. Stanolone (17[beta]-Hydroxy-5alpha-Androstan-3-One)
- 62. Stanozolol (17[alpha]-methyl-17[beta]-hydroxy-[5[alpha]]-androst-2-eno[3,2-c]-pyrazole)
- 63. Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3-one)
- 64. Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1, 4-dien-17-oic acid lactone)
- 65. Testosterone (17[beta]-hydroxyandrost-4-en-3-one)
- 66. Tetrahydrogestrinone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4, 9,11-trien-3-one)
- 67. Trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one)
- (b) Any salt, ester, or isomer of a drug or substance described or listed in subparagraph (a), if such salt, ester, or isomer promotes muscle growth.
- (c) Anabolic steroids intended for administration to cattle or other non-human species are

- exempt from this rule unless such steroids are prescribed, dispensed, or distributed for human use.
- (d) Anabolic steroids with a combination of estrogens intended for administration to hormone deficient women are exempt from this rule unless such steroids are prescribed, dispensed, or distributed to women who are not hormone deficient.
- (7) Hallucinogenic Substances

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403

0940-06-01-.04 Controlled Substances in Schedule IV.

- (1) Schedule IV consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
- (3) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substance, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

	(a)	Alfaxalone	2731
	(b)	Alprazolam	2882
0	(c)	Barbital2	2145
	(d)	Bromazepam	2748
200000	(e)	Camazepam	2749
	(f)	Carisoprodol	3192
	(g)	Chloral betaine	2460
	(h)	Chloral hydrate	2465
	(i)	Chlordiazepoxide2	2744
	(j)	Clobazam	2751

(k)

(1)	Clorazepate	.2768
(m)	Clotiazepam	2752
(n)	Cloxazolam	. 2753
(o)	Delorazepam	2754
(p)	Diazepam	2765
(q)	Dichloralphenazone	2467
(r)	Estazolam	2756
(s)	Eszopiclone	N/A
(t)	Ethchlorvynol	.2540
(u)		2545
(v)	Ethyl Loflazepate	.2758
(w)	Fludiazepam	.2759
(x)	Flunitrazepam	2763
(y)	Flurazepam	
(z)	Fospropofol	
(aa)	Halazepam	2762
(bb)	Haloxazolam	2771
(cc)	Ketazolam	.2772
(dd)	Loprazolam	. 2773
(ee)	Lorazepam	.2885
(ff)	Lormetazepam	. 2774
(gg)	Mebutamate	2800
(hh)	Medazepam	2836
(ii)	Meprobamate	2820
(jj)	Methohexital	.2264
(kk)	Methylphenobarbital (mephobarbital)	2250
(II)	Midazolam	2884
(mm)	Nimetazepam	2837
(nn)	Nitrazepam	2834
(00)	Nordiazepam	. 2838

?	(pp)	Oxazepam	2835
	(qq)	Oxazolam	2839
	(rr)	Paraldehyde	2585
	(ss)	Petrichloral	2591
	(tt)	Phenobarbital	2285
	(uu)	Pinazepam	2883
	(vv)	Prazepam	2764
	(ww)	Quazepam	2881
	(xx)	Suvorexant	200000
	(yy)	Temazepam	2925
	(zz)	Tetrazepam	2886
	(aaa)	Tramadol Other names: Ultram® and Ultracet®	9752
	(bbb)	Triazolam	2887
	(ccc)	Zaleplon	
	(ddd)	Zolpidem	
	(eee)	Zopiclone	2784
(4)	followin	amine. Any material, compound, mixture, or preparation which contains any ag substances including its salts, isomers (whether optical, positional, or geo isomers, whenever the existence of such salts, isomers, and salts of isome	ometric), and
	(a)	Fenfluramine	1670
	(b)	Dexfenfluramine	1670
(5)	followin	erin. Any material, compound, mixture, or preparation which contains any questions are substances, including its salts, isomers, and salts of such isomers, whenever of such salts, isomers, and salts of isomers is possible:	
	(a)	Lorcaserin	1625
(6)	compou	ints. Unless specifically excepted or unless listed in another schedule, any rund, mixture, or preparation which contains any quantity of the following substimulant effect on the central nervous system, including its salts, isomers s:	ostances
	(a)	Cathine ((+)-norpseudoephedrine)	1230
	(b)	Diethylpropion	1610
	(c)	Fencamfamin	1760
	(d)	Fenproporex	
SS-7039 (June 20	016)	21	RDA 1693

	(e)	Mazindol1605
	(f)	Mefenorex
	(g)	Modafinil
	(h)	Pemoline (including organometallic complexes and chelates thereof)
	(i)	Phentermine1640
	(j)	Pipradol
	(k)	Sibutramine
	(I)	SPA ((-)-1-dimethylamino-1,2-diphenylethane)
(7)	compou	ubstances. Unless specifically excepted or unless listed in another schedule, any materia and, mixture, or preparation which contains any quantity of the following substances, g its salts:
	(a)	Pentazocine
	(b)	Butorphanol (including its optical isomers)
	(c)	Eluxadoline (5-[[(2S)-2-amino-3-[4-aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino[methyl]-2-methoxybenzoic acid) (including its optical isomers) and its salts, isomers, and
		salts of isomers 9725

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.05 Controlled Substances in Schedule V.

- (1) Schedule V consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.
- (2) Narcotic drugs containing non-narcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:
 - (a) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
 - (b) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
 - (c) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
 - (d) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
 - (e) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
 - (f) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

- (3) Stimulants. Unless specifically exempted or excluded, or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers:
- (4) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances have a depressant effect on the central nervous system, including its salts:
 - (a) Brivaracetam ((2S)-2-[(4R)-2-oxo-4- propylpyrrolidin-1-yl] butanamide)......2710

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.06 Controlled Substances in Schedule VI.

- (1) Marijuana......7360
- (2) Tetrahydrocannabinols......7370
- (3) Unless specifically excepted or unless listed in another schedule, synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity. Examples include the following drugs or their compounds regardless of numerical designation of atomic positions covered:
 - (a) 1 cis or trans tetrahydrocannabinol, and its optical isomers.
 - (b) 6 cis or trans tetrahydrocannabinol, and its optical isomers.
 - (c) 3. 4 cis or trans tetrahydrocannabinol, and its optical isomers.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.07 Controlled Substances in Schedule VII.

(1) Butyl nitrite and any isomer of butyl nitrite

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.08 Non-narcotic Substances Excluded from Controlled Substances

(1) Non-narcotic substances listed in the most current edition of 21 C.F.R. 1308.22, are excluded from all schedules.

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

0940-06-01-.09 Chemical preparations excluded from Controlled Substances

(1) Chemical preparations listed in the most current edition of 21 C.F.R. 1308.24, are excluded from all schedules.

SS-7039 (June 2016) RDA 1693

- Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.
- 0940-06-01-.10 Veterinary anabolic steroid implant products excluded from Controlled Substances.
 - (1) Veterinary anabolic steroid implant products listed in the most current edition of 21 C.F.R. 1308.26, are excluded from all schedules.
- Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.
- 0940-06-01-.11 Prescription products excluded from Controlled Substances
 - Prescription products listed in the most current edition of 21 C.F.R. 1308.32, are excluded from all schedules.
- Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.
- 0940-06-01-.12 Anabolic steroid products excluded from Controlled Substances
 - (1) Anabolic steroid products listed in the most current edition of 21 C.F.R. 1308.34, are excluded from all schedules.
- Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.
- 0940-06-01-.13 Certain cannabis plant material, and products made therefrom, excluded from Controlled Substances
 - (1) Certain cannabis plant material, and products made therefrom, that contain tetrahydrocannabinols listed in the most current edition of 21 C.F.R. 1308.35, are excluded from all schedules.

Authority: Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403.

SS-7039 (June 2016) RDA 1693

* If a roll-call vote was necessary, the vote by the Agency on these rulemaking hearing rules was as follows:

Board Member	Aye	No	Abstain	Absent	Signature (if required)			
					(ii roquirou)			
I certify that this is an accurate and complete copy of rulemaking hearing rules, lawfully promulgated and adopted by the Tennessee Department of Mental Health and Substance Abuse Services (board/commission/ other authority) on (mm/dd/yyyy), and is in compliance with the provisions of T.C.A. § 4-5-222.								
I further certify the following:								
Notice of Rulemaking	Hearing filed with	the Department of	f State on:	11/04/16)				
Rulemaking Hearing(s) Conducted on:	(add more dates).	(01/04/17)					
		Date:	/					
		Signature:						
	Nar		rie Williams	Name of the second				
	Т		mmissioner, Tenness d Substance Abuse S		Mental Health			
	Subscribed and	sworn to before m	ne on:					
		Notary Public Sign	ature:					
My commission expires on:								
		Date:						
A A		Signature:						
addillion.	Nar	me of Officer: _Joh	nn J. Dreyzehner, MD	, MPH				
	T	itle of Officer: Co	mmissioner, Tenness	ee Department of	Health			
	Code and the ad							
		and sworn to before me on:						
	Notary Pub	lic Signature:						
	My commissio	n expires on:						

All rulemaking hearing rules provided for herein have been examined by the Attorney General and Reporter of the State of Tennessee and are approved as to legality pursuant to the provisions of the Administrative Procedures Act, Tennessee Code Annotated, Title 4, Chapter 5.

Herbert H. Slatery III Attorney General and Reporter Date **Department of State Use Only** Filed with the Department of State on: Effective on Tre Hargett Secretary of State

Public Hearing Comments

One copy of a document containing responses to comments made at the public hearing must accompany the filing pursuant to T.C.A. § 4-5-222. Agencies shall include only their responses to public hearing comments, which can be summarized. No letters of inquiry from parties questioning the rule will be accepted. When no comments are received at the public hearing, the agency need only draft a memorandum stating such and include it with the Rulemaking Hearing Rule filing. Minutes of the meeting will not be accepted. Transcripts are not acceptable

TDMHSAS Responses to Comments about
Rules Chapter 0940-06-01
Consideration of Chapter 0940-06-01 Controlled Substances
Rulemaking Hearing Held on January 4, 2017

*The Department has attempted to present the following comments in a form that is both easy to read and accurate to the intent of the commenter. In rare cases, the Department made technical edits to increase the readability of a comment. Please forgive any typographical errors in both the comments and responses.

JIMMY MUSICE, SENIOR POLICY ADVISOR AND ATTORNEY, TENNESSEE BUREAU OF INVESTIGATION: I'm here to let you know what our stance was and that was to recommend that etizolam be added to Schedule I in the rules. And I'm going to let Glenn Everitt give you an overview as to why we feel that way.

GLENN EVERITT, SUPERVISING SPECIAL AGENT FORENSIC SCIENTIST, TENNESSEE BUREAU OF INVESTIGATION: We've been monitoring etizolam for the past few years and it's exponentially grown over the years. We started out seeing it in 2014 and saw a few cases and then it grew from there. In 2015 we saw 29 cases and so far this year we've seen 94 cases. A lot of times we see etizolam in combination with Fentanyl and not that we don't see it as a powder by itself but we general see it in the fake Xanax tablets that mimic Alprazolam. There are different stamps they make for the tablets – the Xanax IIs or the GG2-49s. We've being seeing those and as far as I know the FDA does not have any use for that. I know that it has been used in other countries as a benzodiazepine but to my knowledge the FDA has not regulated that.

Mr. Musice: I would like to add that states surrounding Tennessee have scheduled it as a Schedule I – Alabama, Arkansas, Mississippi, Virginia and Florida. Most of those states did so in 2014 when they first began to see it. We've seen it used as a date-rape drug in the field. Glenn talked about some of the lab results going from 3 to 29 then to 94 but we've also see an increase on the toxicology side and that's when someone is pulled over for DUI and they may do a blood draw on them. In 2015 state-wide, 18 results contained etizolam and that was only used in the Middle District lab so it wasn't state-wide. But so far in 2016 state-wide it's up to 34. So, not only have we seen the increase through our drug agents purchasing and going after organizations but we're seeing it in the blood results of drivers, driving intoxicated on Tennessee roads.

Kurt Hippel: So you see an abuse potential for this substance?

Mr. Musice: Absolutely.

Mr. Everitt: Yes, definitely. As it stands now because our analogue law etizolam does not fit the legal definition of an analogue in the T.C.A. the way it's currently written it won't even though if you are asking me as a scientist is it an analogue, yes. Does it have the same affects as a benzodiazepine, yes. But as our law is currently written for the analogue, you can't make that jump to say that it's legally an analogue. So really there's no recourse to prosecute it. So therefore we're seeing it increasing every year.

Kurt Hippel: Dr. Geminn, do you have any questions?

Dr. Geminn: My question would be, with your agents in the field, what is the source? Because it's not approved for use in the United States so I assume it can't legally be imported.

Mr. Musice: Without getting too specific, there are ways throughout the Internet to obtain this substance and get it here, and get it here in bulk. I don't mean it's coming over in sandwich bags but full kilos being shipped here to Tennessee. What they do, they'll take that product add a binder and usually... (to **Glenn Everitt**) what else will

they add to it when they're going to stamp the pill?

Dr. Geminn: Starch.

Mr. Everitt: Polymeric acid, uric acid, vositol, a number of things they can do.

Mr. Musice: But mainly, because right now etizolam is approved for use in Japan, India and Italy, we see more of Asian markets that are creating the etizolam. And like other drugs sometimes the Asians use the Mexican cartels as their distribution resource and a way to get it into the United States. But I didn't want to say that's the only way because like I said, you can order it off the Internet on certain websites.

Dr. Geminn: I don't know if you've researched it at all, but Georgia made it a Schedule IV which is with the other benzodiazepines. Do you have any idea why maybe that state made it a Schedule IV? Are there arguments for making it in any another Schedule than a Schedule I?

Mr. Musice: My assumption would be is that because it acts and mimics a benzodiazepine that they placed it in Schedule IV with all the other benzodiazepines. But our position would be that because the United States does not have a recognized reason for etizolam then that would put it in Schedule I with the others.

Dr. Geminn: That's all the questions I have.

Kurt Hippel: Great. Dr. Loyd?

Dr. Loyd: I want to follow up on Dr. Geminn's question. So, is this similar to what's happening with fentanyl right now?

Mr. Everitt: Yes, it can be. And we're often seeing it mixed with the fentanyl when creating counterfeit opioids.

Dr. Loyd: Okay, Thank you.

Kurt Hippel: Thank you. Does anyone else on the Department panel have a question for the TBI? Thank you Gentlemen, we will take these comments and recommendations under full consideration. That is the end of my list of people who would want to make comments today. I will look through the room one last time to make sure no one else wants to say anything.

Dr. Geminn: One more question for the TBI, I'll repeat their answer if they can't hear. Have there been any deaths associated with etizolam? Any like post mortem drug....

Mr. Everitt: Yes and No. Yes, because the deaths that we've seen, fentanyl or heroin...

Dr. Geminn: It's "with"...

Mr. Everitt ... or any combination with etizolam. I'm sorry. I'm not sure...

Dr. Geminn: You can't say what the causative agent is but it's been associated in those screens for deceased individuals?

Mr. Everitt: Right. I don't know if etizolam acts like an antagonist to enhance the effects of the heroin or fentanyl. I'm not exactly sure as to why they are putting that in with heroin or fentanyl.

Kurt Hippel: But it is present in lab tests where someone has died?

Mr. Everitt: Correct

Dr. Geminn: Has overdosed?

Mr. Everitt: Yes.

Dr. Loyd: I think we make the assumption that it's a benzodiazepine or very close. So it potentiates the effect of the fentanyl. That's generally the cause. It's got a little bit different chemical structure; its half-life

is a little longer too. Theoretically that makes it have a less potential for abuse, but I don't think that's what we are looking at here. We're looking at it as there being no medical valid reason to be used in the United States, not FDA approved. And then also the potential toxicity.

TDMHSAS Response: After considering the information provided by the Tennessee Bureau of Investigation and pursuant to T.C.A. 39-17-403(a) & (b), the substance etizolam, also known as Etilaam, Etizola, Sedekopan, Pasaden, Depas, will be scheduled as a Schedule 1 controlled substance in this rule (TDMHSAS Rule Chapter 0940-06-01 Controlled Substances). The findings, as set out by T.C.A. 39-17-403(a), regarding the scheduling of etizolam as a Schedule 1 controlled substance are as follows:

1. The actual or relative potential for abuse:

Etizolam is a thienodiazepine which has a chemically related structure to a class of substances known as benzodiazepines. Benzodiazepines are widely prescribed drugs with a known abuse potential while etizolam currently does not have an accepted medical use in the United States.¹ While etizolam does have a medically accepted use in a few international countries, it typically requires a prescription and is usually considered a controlled substance only when considering benzodiazepines as a whole. Due to etizolam being a benzodiazepine analog, it does have anxiolytic effects, but has a short duration of action which may lead to dependence.²

2. The scientific evidence of its pharmacological effect, if known:

Since etizolam is a benzodiazepine analog, it possesses anxiolytic, anticonvulsant, sedative-hypnotic, and muscle relaxant effects similar to other benzodiazepines.

3. The state of current scientific knowledge regarding the substance:

Etizolam was developed in Japan and is registered as a medicine in at least 3 countries: Japan, Italy, and India. The majority of current scientific knowledge regarding etizolam is due to the study of benzodiazepines as a whole.³

4. The history and current pattern of abuse:

Etizolam has a limited history of abuse due to lack of specific tracking through drug screens. According to the Tennessee Bureau of Investigation, drug screens showing positive for etizolam have been increasing, with 29 cases in 2015 and 94 cases in 2016.

5. The scope, duration and significance of abuse:

Etizolam is a benzodiazepine analog and has a generally similar pharmacological profile to the benzodiazepine class. Approximately 30% of the 1,045 deaths in 2015 caused by opioid overdose also involved benzodiazepine use in Tennessee. Tennessee's prescription drug overdose rate is 26% above the national average and Tennessee leads the nation in the number of controlled substance prescriptions per capita.

6. The risk to the public health:

Benzodiazepines and analogs such as etizolam may be abused or may be used in combination with other drugs of abuse to produce additive results. Etizolam is also not currently classified as a controlled substance, which poses a threat to public safety since prosecutors are unable to prosecute anyone with possession or intention for distribution of this compound.

7. The potential of the substance to produce psychic or physiological dependence liability:

In animal experiments, etizolam has been shown to be approximately 10 times more potent than diazepam (Valium®). Dependence may develop with regular use of benzodiazepines, which may precipitate withdrawal syndrome when the drug is discontinued.

¹ Drug and Chemical Evaluation Section: Etizolam. (Oct 2014). Office of Diversion Control, Drug Enforcement Administration, Retrieved January 5, 2017 from https://www.deadiversion.usdoj.gov/drug chem info/etizolam.pdf

^{2,3} Gupta, S., & Garg, B. (2014). A case of etizolam dependence. Indian Journal of Pharmacology, 46(6), 655–656. http://doi.org/10.4103/0253-7613.144943

8. Whether the substance is an immediate precursor of a substance already controlled under this section:

This substance is not an immediate precursor of a substance already controlled in Tennessee. Although this is an analog, the chemical structure of etizolam does not put it under our previous actions for controlling analogs and precursors to controlled substances.



Regulatory Flexibility Addendum

Pursuant to T.C.A. §§ 4-5-401 through 4-5-404, prior to initiating the rule making process, all agencies shall conduct a review of whether a proposed rule or rule affects small business.

These rules will not affect small businesses. Although, some pharmacies qualify as small businesses, the changes to the controlled substances schedules promulgated by these rules should not change the daily operations of those pharmacies.



Economic Impact Statement

1) The type or types of small business and an identification and estimate of the number of small businesses subject to the proposed rule that would bear the cost of, or directly benefit from the proposed rule.

These rules will not affect small businesses.

2) The projected reporting, recordkeeping and other administrative costs required for compliance with the proposed rule, including the type of professional skills necessary for preparation of the report or record.

These rules will not affect reporting, recordkeeping, or other administrative costs of small businesses.

3) A statement of the probable effect on impacted small businesses and consumers.

These rules will not affect small businesses.

4) A description of any less burdensome, less intrusive or less costly alternative methods of achieving the purpose and objectives of the proposed rule that may exist, and to what extent the alternative means might be less burdensome to small business.

There is no less burdensome, less intrusive or less costly alternative methods of achieving the purpose and objectives of the proposed rules.

5) A comparison of the proposed rule with any federal or state counterparts.

These rules compare favorably with the federal controlled substances schedules as T.C.A. § 39-17-403 requires the Tennessee Department of Mental Health and Substance Abuse Services (TDMHSAS) to schedule substances if those substances have been designated as controlled substances by federal regulations promulgated by the U.S. Department of Justice Drug Enforcement Administration (DEA), unless TDMHSAS, upon agreement with the Tennessee Department of Health (TDH), decides otherwise.

6) Analysis of the effect of the possible exemption of small businesses from all or any part of the requirements contained in the proposed rule.


These rules will not affect small businesses.



Impact on Local Governments

Pursuant to T.C.A. §§ 4-5-220 and 4-5-228 "any rule proposed to be promulgated shall state in a simple declarative sentence, without additional comments on the merits of the policy of the rules or regulation, whether the rule or regulation may have a projected impact on local governments." (See Public Chapter Number 1070 (http://state.tn.us/sos/acts/106/pub/pc1070.pdf) of the 2010 Session of the General Assembly)

TDMHSAS estimates that these rules will not have a projected financial impact on local governments.



Additional Information Required by Joint Government Operations Committee

All agencies, upon filing a rule, must also submit the following pursuant to T.C.A. § 4-5-226(i)(1).

(A) A brief summary of the rule and a description of all relevant changes in previous regulations effectuated by such rule;

The lists of controlled substances for all schedules were revised to ensure consistency with Part 1308 of Title 21 of the Code of Federal Regulations (C.F.R.) and T.C.A. §§ 39-17-406, 39-17-408, 39-17-410, 39-17-412, 39-17-414, and 39-17-416.

0940-06-01-.01 names controlled substances within Schedule I including opiates, opium derivatives, hallucinogenic substances, depressants, and stimulants. Etizolam, although not federally scheduled, has been scheduled as a Schedule I controlled substance in this rule (see TDMHSAS Findings on p. 29 of this document). 0940-06-01-.02 names controlled substances within Schedule II including opium and opiates, substances produced by extraction from vegetable origin or chemical synthesis, opiates, stimulants, depressants, hallucinogenic substances, immediate precursors to amphetamine and methamphetamine, and PCP. 0940-06-01-.03 names controlled substances within Schedule III including stimulants, depressants, nalorphine, narcotic drugs, anabolic steroids, and hallucinogenic substances.

0940-06-01-.04 names controlled substances within Schedule IV including narcotic drugs, depressants, fenfluramine, and stimulants.

0940-06-01-.05 names controlled substances within Schedule V including narcotic drugs containing non-narcotic active medicinal ingredients, stimulants, and depressants.

0940-06-01-.06 names controlled substances within Schedule VI including marijuana and tetrahydrocannabinols.

0940-06-01-.07 names controlled substances within Schedule VII including butyl nitrite and any isomer of butyl nitrite.

0940-06-01-.08 incorporates by reference exclusions for non-narcotic substances listed in the most current edition of 21 C.F.R. 1308.22 including those sold lawfully over the counter without a prescription.

0940-06-01-.09 names chemical preparations excluded from controlled substances.

0940-06-01-.10 names veterinary anabolic steroid implant products excluded from controlled substances.

0940-06-01-.11 names prescription products excluded from controlled substances.

0940-06-01-.12 names anabolic steroid products excluded from controlled substances.

0940-06-01-.13 names certain cannabis plant material, and product made therefrom, excluded from controlled substances.

- (B) A citation to and brief description of any federal law or regulation or any state law or regulation mandating promulgation of such rule or establishing guidelines relevant thereto;
- 21 U.S.C. 812: Establishes schedules of controlled substances.
- 21 C.F.R. 1308: Contains schedules of controlled substances set forth by the U.S. Department of Justice Drug Enforcement Administration.
- T.C.A. § 4-4-103: Empowers the Commissioner of each department to prescribe regulations.
- T.C.A. § 33-1-302: Empowers the Department to make and enforce rules necessary for the efficient financial management and lawful operation of facilities and services.
- T.C.A. § 33-1-303: Defines powers of the Commissioner including rulemaking authority.
- T.C.A. § 33-1-305: Empowers the Commissioner of the Department of Mental Health and Substance Abuse Services to adopt rules to fulfill the Department's responsibilities.
- T.C.A. § 33-1-309: Requires the Department to adopt all rules in accordance with the Uniform Administrative Procedures Act.
- T.C.A. § 39-17-403: Requires the Commissioner of the Department of Mental Health and Substance Abuse Services, upon agreement of the Commissioner of the Department of Health, to control substances according to certain guidelines.
- **(C)** Identification of persons, organizations, corporations or governmental entities most directly affected by this rule, and whether those persons, organizations, corporations or governmental entities urge adoption or rejection of this rule;

Examiners, and Pharmacy; the TennCare Inspector General and the TN Bureau of Investigation. The Department received comments from the TN Bureau of Investigation regarding this rule during the rulemaking hearing held for this rule on January 4th, 2017. These were the only comments received regarding this rule and TDMHSAS adopted the action proposed by the comments from the TN Bureau of Investigation.

(D) Identification of any opinions of the attorney general and reporter or any judicial ruling that directly relates to the rule or the necessity to promulgate the rule;

There are no opinions of the Attorney General and Reporter that directly relate to these rules.

(E) An estimate of the probable increase or decrease in state and local government revenues and expenditures, if any, resulting from the promulgation of this rule, and assumptions and reasoning upon which the estimate is based. An agency shall not state that the fiscal impact is minimal if the fiscal impact is more than two percent (2%) of the agency's annual budget or five hundred thousand dollars (\$500,000), whichever is less;

It is estimated that these rules will not have a fiscal impact on state and local government revenues and expenditures.

(F) Identification of the appropriate agency representative or representatives, possessing substantial knowledge and understanding of the rule;

Wesley Geminn, Chief Pharmacist, TDMHSAS Kurt Hippel, Director of Legislation, Rules & Privacy, TDMHSAS

(G) Identification of the appropriate agency representative or representatives who will explain the rule at a scheduled meeting of the committees;

Wesley Geminn, Chief Pharmacist, TDMHSAS Kurt Hippel, Director of Legislation, Rules & Privacy, TDMHSAS

(H) Office address, telephone number, and email address of the agency representative or representatives who will explain the rule at a scheduled meeting of the committees; and

Wesley Geminn, Chief Pharmacist
Tennessee Department of Mental Health and Substance Abuse Services
6th Floor, Andrew Jackson Building
500 Deaderick Street
Nashville, TN 37243
Wesley.Geminn@tn.gov
615-532-6736

Kurt Hippel, Director of Legislation, Rules & Privacy
Tennessee Department of Mental Health and Substance Abuse Services
5th Floor, Andrew Jackson Building
500 Deaderick Street
Nashville, TN 37243

Kurt.Hippel@tn.gov 615-532-9439

(I) Any additional information relevant to the rule proposed for continuation that the committee requests.

N/A				